How the Right Is Starting a Psychological War by Targeting the Old and Ageing – The Wire

When Mahatma Gandhi was assassinated, he was a frail man, disappointed and also withdrawn from national politics. He was 78 years old, and one thought it was a travesty that a person who spoke tirelessly of non-violence all his life met a violent death. But it now looks it was not happenstance; almost 70 years later we are now witnessing a series of events that echo it.

It began with the murders of Govind Pansare, Narendra Dabholkar and Kalburgi all of them into their 70s, and more recently the arrest of Varavara Rao, and now Stan Swamy, both into their 80s. The silent but unmistakable ageism in the way the Right in India thinks will hold important clues to how they see life and the nihilism, and contempt for anyone considered vulnerable. What can explain the series of killings and arrests of octogenarians, and what could be the possible message that they wish to communicate?

From the left: Govind Pansare, Narendra Dabholkar, Varavara Rao and Stan Swamy. Credit: PTI

Predatory state

There seems to be a mix of factors as to how activists who are old, ageing and ailing seem to be picked up and made a spectacle of. It immediately communicates certain ruthlessness and recklessness. Varavara who was once known to be a powerful public speaker was struggling to find the right words and who was known to have an elephants memory failing to recognise his own family. All stress-induced symptoms also come with ageing. But repeated refusals to grant bail and machinations to keep him in prison are a clear message of seeing this as a fight to finish.

It symbolises a predatory culture where one can either be a victor or the vanquished. Targeting the old seems to bring a sense of doomsday where there is no escape for the rest if the old and ailing are not spared.

It seems to also resonate with the idea of a strong nation that has little space and patience for the unproductive bodies. It brings back the memories of Nazi rule that targeted not just the Jews but also the disabled White German kids and put them through the same gas chambers. It symbolises a kind of productivism of both the market and the nation. If one is not of use and not productive it is not immoral to dispense with them.

This, figuratively, seems to stand in opposition to the young and productive nation that is looking ahead. By default making a spectacle of the old and ageing seem to also signify that the values and ideologies they stood for are outdated and irrelevant. Shrinking bodies become the templates for conveying coded message of fading ideas and upend value system.

The recent video of Stan Swamy complaining of ailments and yet remaining steadfast for the values he stood for in fighting for the tribals can send a message of unflinching commitment, but it can also mean they are stretching themselves at a time when they needed to retire and spend time with grandkids, be contemplative and await the inevitable.

In Hindu philosophy, it signifies an age to move towards vanaprastha and sanyasa referring to giving up worldly pursuits. It goes with the symbolism of Prime Minister Narendra Modi meditating in the cave and taking a lonely walk between the election results and announcing 75 as a cut off year to hold administrative posts in state or central governments. He had moved the ageing leaders to a freshly minted Margadarshak Mandal.

The Right seems to believe that given the cultural codes of Hindu way of life, dispensing with the old will meet less protest and resistance from the society. It creates a scope for more fear and less resistance. The suffering they are being put through seems to be seen through the prism of a calculus of how many more years are really left and society would forgive and may be even forget the excesses more easily but the message of being ruthless and un-pardoning slowly seeps in.

Also read: Modi 2.0: A Coming-of-Age Drama for Majoritarianism and Authoritarianism

Political nihilism

While the arrests of young men brings a spirit of resistance that can inspire the society, incarcerating the old makes us more contemplative, look at the meaning and purpose of life, and we associate it less with action. It brings in a sense of nihilism, reminding us of the inevitability of death and futility of suffering. It reminds us of a time for other worldly pursuits as is poignantly reminded to us in the film Mukti Bhawan. In fact, in much of religious philosophy, death is Moksha, a kind of liberation for the corporeal self and body and is not something to grieve over, much less resist.

Ageing reminds us of a sense of loneliness that awaits us with a deep sense of vulnerability. It reminds us of the need to plan for ones safety and care and pursuit of collective interest and heroic activism can cost you not just your life but the bare needs necessary for an ageing body. It can have deep roots in psychology of creating innate insecurity; the Right consciously targets sites that harbour our latent and dark selves.

Psychoanalyst Sudhir Kakar notes how rumours of poisoned milk being sold are spread during communal riots as figuratively milk symbolises a primordial maternal security. It can arouse latent fears and insecurities and primordial instinct for violence. In killing and arresting the old and ageing, the Right is targeting a psychological warfare on its own society to disempower and silence it.

It is an empowering irony to watch and get inspired by the dadis of Shaheen Bagh where Bilkis Bano symbolises the new hope. Her age evokes happiness, love and mischief. It transcends social boundaries of religion and place. Time magazine listed her in 100 most influential people of 2020.

Shaheen Bagh, on one of the evenings in March. Photo: Rayees Amin

Life moves through dialectics, as the current regime looks at the underside of age, dadis of Shaheen Bagh are reminding us of what Mark Twain once famously said: Age is an issue of mind over matter, if you dont mind, it doesnt matter. Age brings the best of lighter side of life and reminds us of taking life with a pinch of salt and standing for causes well beyond ones immediate interest could possibly be the most meaningful way of living ones life. Collective resistance needs to upturn the cynical spectacle in resisting for and celebrating the lives of these ageing soldiers of salvation and emancipation.

Ajay Gudavarthyis an associate professor at the Centre for Political Studies, JNU.

Follow this link:

How the Right Is Starting a Psychological War by Targeting the Old and Ageing - The Wire

Can the GOP ever redeem itself? – The Week

Democrats look well poised to beat President Trump and the Republican Party in this fall's election. There are some observers who hope that a good electoral thrashing will bring Republican leaders to their senses and cause them to steer a course away from the party's unofficial platform of revanchism, culture wars, and white identity politics toward a less-alarming path.

But defeat no matter how large or ignominious probably won't redeem the GOP, nor cure it of its Trumpist excesses.

A landslide victory for Democratic candidate Joe Biden "would turn the Trump era of nihilism, tribalism, and cruelty into a cautionary tale of extremism, illiberalism, and, above all, failure," Andrew Sullivan wrote last week. He added: "And a landslide is the only thing that can possibly, finally break the far right fever that has destroyed the GOP as a legitimate right-of-center political party, and turned it into a paranoid, media-driven, fact-free festival of fear and animus."

This might sound familiar. Sullivan made a similar case in 2007, arguing in The Atlantic for the candidacy of Barack Obama as a means of repudiating the Boomer-driven culture wars that had culminated in the multiple disasters Iraq, Hurricane Katrina, the Great Recession of George W. Bush's presidency.

"At its best, the Obama candidacy is about ending a war not so much the war in Iraq, which now has a momentum that will propel the occupation into the next decade but the war within America that has prevailed since Vietnam and that shows dangerous signs of intensifying, a nonviolent civil war that has crippled America at the very time the world needs it most," Sullivan wrote. "It is a war about war and about culture and about religion and about race. And in that war, Obama and Obama alone offers the possibility of a truce."

Obviously, that's not how things actually worked out.

Republican leaders did distance themselves from Bush, but Obama's landslide election victory sparked a backlash that ushered in the Tea Party, Glenn Beck's ugly heyday, GOP intransigence, and birtherism.

When Obama won big again in 2012, there was a moment when the party's leaders appeared ready to set a new course. The Republican National Committee produced a postmortem report that proclaimed voters perceived the party as belonging to "stuffy old men." The RNC vowed to plunge its resources into reaching out to minority voters. Sen. Marco Rubio (R-Fla.) eyeing a 2012 run for the presidency even took the lead on crafting a bipartisan immigration reform bill as part of an effort to soften the GOP's image.

The bill never gained traction. Conservatives bludgeoned Rubio for his perceived softness on immigration. Republican voters chose Donald Trump and his border wall in the 2016 primaries, despite the obvious agitation it caused the party establishment. But when Trump was elected, that establishment including Rubio fell in line.

So even if Trump loses the election by double-digit margins, as several recent polls have indicated he might, recent history doesn't augur Republican repentance. The party's Trump-loving base voters aren't going anywhere. Neither is Trump. It is doubtful he would follow the lead of his predecessors and recede into the background after leaving office instead we probably can expect a Mar-a-Lago tweetstorm to keep the former reality star in the spotlight and stirring up trouble for as long as he is able.

One big election defeat, or two, might not convince Republicans of the errors of their ways. It might take a generation of losses, of being deprived of power, to do the trick. Republicans were locked out of the White House for 20 years starting with Franklin Roosevelt's election in 1932, and only reclaimed office after Dwight Eisenhower a hugely popular war hero whom Democrats had also tried to woo as their candidate took office and governed as a post-New Deal moderate. Similarly, Democrats spent most of the post-Richard Nixon era in the wilderness, given a break only by the Watergate-driven election of Jimmy Carter, and getting relief only when Bill Clinton arrived on the scene in 1992 to steer the party toward the center.

Maybe this time will be different.

Want more essential commentary and analysis like this delivered straight to your inbox? Sign up for The Week's "Today's best articles" newsletter here.

Go here to see the original:

Can the GOP ever redeem itself? - The Week

Passenger’s ode to quarantine | The Current – The Current – The Student-Run Newspaper of Nova Southeastern University.

In early July, singer-songwriter Passenger, known for his 2013 hit Let Her Go, released his new studio album titled Patchwork. Although this is his twelfth studio album, there is one major difference that Patchwork boasts: it was written and recorded almost entirely during the COVID-19 lockdown.

The album sets the tone from the beginning with Sword in the Stone, which immediately tells the listener that this is going to be a concept album about the pandemic. Just when you think that you have heard enough about it, the first song brings about the realization that we have survived a major historical event. Passenger sings about the pain and frustration we endured on the rollercoaster that was the early months of the pandemic. For many, this is still a reality. There is a sense of vulnerable honesty when he begins the song by asking how his darling is and then sharing the unbearably hard time he has been having.

Year on Year, Day by Day gives the listener a shoulder to lean on and the assurance that, in time, everything will be okay. Passenger walks the fine line between nihilism and stoicism near the end of the song, calling life a comedy show and how if you live longer than expected, the Queen gives you a medal. In the albums titular track Patchwork, apart from the cozy melody that gives any lullaby a run for its money, the song is a love letter to the tenacity of humankind and the real-life superhero ability that is being able to move on. Patchwork encourages the listener to look at everything weve built and to, metaphorically, sew another square onto our quilt.

Venice Canals is one of those songs that makes you actually go and learn something. The track speaks to the numerous natural wonders that had returned during the quarantine. The stars of Beijing, the birds of Times Square and the fish in the Venice Canals. During the lockdown, the waters of the Venice Canals were clear enough to see the fish. Passenger speaks to a beautiful silver lining in the wake of the global chaos that began in March. He sings dont get me wrong, this aint no happy song, meaning that the human world is still in ruins, but ironically, the natural world is flourishing when it was previously the other way around.

Queenstown is the track on the album most deserving of being a single, meaning its really good. If one looks deeper, under its comforting chord progressions and warm verses, you can see its not just about a good time in a town in New Zealand. This indie, playing-guitar-by-candlelight ballad is about the good memories with friends and family before we had to wear masks that hide our smiles, stay six feet apart, do away with hugs and put on hand sanitizer every time we go out. Its the type of nostalgia that brings more sadness than euphoria.

Swimming Upstream is a very refreshing upbeat song, providing a little motivation boost for those who need it. This song is for those who feel like no matter how hard they try, life just does not seem to be leading them anywhere. He relates it to swimming upstream and encourages listeners to keep swimming. Somebody You Loved is the only cover on the album, originally performed by Lewis Capaldi, but Passengers version does it just like you would expect him to: soft guitar picking, overlapping vocals and an artistic touch of electric guitar here and there.

The album ends with Summer Rain, which sums up the entire album in one song seemingly reinforcing the idea, in case the listener has not understood it yet. The pandemic was and continues to be horrible. It has caused massive financial suffering, moral debates, serious sickness, and in the worst cases, death.However, comfort can be found in the fact that it happened to everyone. In this divided time, if we cant relate to each other on anything, at least we can share and understand each others pain.

Related

More here:

Passenger's ode to quarantine | The Current - The Current - The Student-Run Newspaper of Nova Southeastern University.

Strong government response needed in COVID battle – Harvard Gazette

A worldwide forum convened to share insights gleaned from the fight against the novel coronavirus highlighted the importance of a strong, coordinated government response as crucial to stopping its spread, both within a country and internationally.

It has never been more important for us than it is now to shoulder the responsibility to respond quickly and effectively to the threat posed to human lives and to the health of our communities, local, regional, national, and global, said Mark Elliott, vice provost for international affairs and the Mark Schwartz Professor of Chinese and Inner Asian History. Introducing Global Perspectives on COVID-19, which brought together medical and scientific participants from China, Italy, South Africa, and the U.S. on Wednesday, Elliott characterized the pandemic as a monumental public health crisis.

There is strong evidence, however, that it is a crisis that responds to lockdown. Zhong Nanshan, professor of respiratory medicine at Guangzhou Medical University, discussed the speed of containment in Wuhan, China, where COVID-19 was first documented on Dec. 7, its severity apparent by Jan. 20, and the city locked down by Jan. 23. The containment appeared to work, said Zhong, who is also director of the National Clinical Research Center for Respiratory Disease, as cases in China leveled out at approximately 80,000 by March 1. To date, they have increased by only about 10,000, which he attributed to imported cases.

Strong action by the central government is still the most effective way to block transmission, Zhong said. The next step, however, is the development of vaccines, he said, citing the urgent need for international collaboration.

Fabio Ciceri, scientific director of the San Raffaele Scientific Institute, said earlier interventions and the introduction of some important treatments in Northern Italy helped bring down mortality rates in the San Rafaelle hospital from 24 percent to less than 1 percent. As the country prepares for a possible second wave, perhaps as soon as December, he stressed the importance of early testing and tracing, networking between hospitals, and referrals to COVID-19 care hubs. These centers have new clinical trials with investigational treatments, as well as post-COVID-19 clinics, which follow up on long-term care and management of late and lingering symptoms, he said.

Salim Abdool Karim, director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and member of the African Task Force on Coronavirus, Africa Centres for Disease Control and Prevention (Africa CDC), said that in Africa the coronavirus has infected approximately 1.5 million people and killed more than 36,000, a fatality rate of approximately 2.4 percent. COVID-19 now appears to be in decline on the continent, though that could be from underreporting or under-testing in some of its countries, or the facts that Africas population skews significantly younger than Europe or North Americas, and fewer of its citizens travel internationally.

However, he too credited a coordinated government response with saving lives. Citing a strong and consistent political commitment by the African Union, he noted that Africa CDC quickly set up a platform for a coordinated response for supplies. We were not competing against each other for, say, test kits, he said. This coordinated response also engaged the public. Karim pointed to a tradition of working for the collective good, which Karim called the principle of ubuntu, translated as I am, because you are.

You are safe because I am safe, Karim said. Our collective interdependence is how well protect ourselves going forward.

George Q. Daley, Harvard Medical Schools dean of the faculty of medicine, noted how in its 10th month, the pandemic has passed a grim milestone of 1 million deaths. Vanquishing COVID-19 will depend critically on how we learn from each other and how we collaborate as a global biomedical community united against this common threat, he said. Meanwhile, Megan Murray, the Ronda Stryker and William Johnston Professor of Global Health at HMS, discussed the possibility of zoonosis, the leap of pathogens from animals to humans and how it has been enabled by climate change and magnified by climate migration and the mass displacement of marginalized people. As the natural environment is destroyed, we can expect to see more such disease, she said, which will disproportionately affect the poor. Epidemics expose the fault lines of our society.

Paul Farmer, Kolokotrones University Professor of Global Health and Social Medicine and chair of Harvard Medical Schools Department of Global Health and Social Medicine, wrapped up the conference with a look at what doesnt work: contact nihilism, in which governments give up tracing contacts, and clinical nihilism, in which they focus solely on containment and almost give up on treatment.

When you see claims that the treatment of a pathology in a pandemic is impossible, unfeasible, not cost effective, make sure youre not seeing clinical nihilism, he said. Theres always a gap between the development of a new therapeutic and its widespread distribution.

The forum was co-sponsored by Harvard Medical School and the Massachusetts Consortium on Pathogen Readiness (MassCPR) as part of Worldwide Week at Harvard.

Link:

Strong government response needed in COVID battle - Harvard Gazette

Exposing the Fault Lines – Harvard Medical School

This article is part of Harvard Medical Schoolscontinuing coverageof medicine, biomedical research, medical education and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.

Nine months into the coronavirus pandemic that has now killed more than one million people, global health experts have gained a clearer understanding of what has to happen to successfully contain the disease and protect populations going forwardand its going to require close coordination and collaboration.

They shared those hard-won lessons recently at a special, virtual gathering of international scientists and clinicians hosted by Harvard.

Get more HMS news here

Conquering this contagion will depend on unraveling the biology of the virus, understanding the pathophysiology of the disease, and developing treatments and vaccines to halt its spread, said George Q. Daley, dean of Harvard Medical School, in his welcoming remarks at the online symposium, which focused on developing solutions to the global health crisis.

Vanquishing COVID-19 will depend critically on how we learn from each other and how we collaborate as a global biomedical community united against this common threat, he added.

Scientists from the HMS-ledMassachusetts Consortium on Pathogen Readiness(MassCPR)in Boston, and colleagues in China, Italy and South Africa convened via teleconference on Oct. 7 to examine the impact of and response to COVID-19 in some of the early pandemic hot spots and to share lessons learned from past epidemics.

The session was part ofWorldwide Week at Harvard, and it featured researchers and clinicians who have spent decades fighting some of the worlds deadly outbreaks of infectious disease.

Mark Elliott, vice provost for international affairs and the Mark Schwartz Professor of Chinese and Inner Asian History at Harvard, welcomed participants to the remote event, noting that MassCPR is a historic partnership benefitting people around the world as nations join to confront COVID-19s unprecedented threat to life, health and well-being.

In just 10 months, Daley said, the pathogen has exacted an extraordinary human tollnot only through a high mortality rate, widespread infection, and the severity of illness it has wrought but also through economic devastation and radical transformations in the way societies are socializing, working and learning.

To help put COVID-19 in context, Megan Murray,the Ronda Stryker and William Johnston Professor of Global Health in the Blavatnik Institute at Harvard Medical School and director of research atPartners In Health, shared a historical perspective from epidemics past and a current view of ongoing outbreaks.

Murray described several of the most catastrophic epidemics of infectious disease in the 20th and 21st centuries, including outbreaks of pneumonic plague among migrant hunters in Mongolia, Nipah virus among farmers and meat processing workers in Malaysia, and the ongoing series of Ebola outbreaks that have ravaged the Democratic Republic of Congo.

The common threads that bind these outbreaks, she said, are economic and ecological disruption, which put impoverished people with limited access to health care in direct contact with deadly pathogens.

Murray noted that it is not just novel pathogens that pose a particular risk: tuberculosis, like COVD-19, does not cause symptomatic disease in most of the people infected and thrives where people live in crowded conditions with poor ventilation, indoor air pollution and comorbidities of chronic diseases associated with poverty.

The lesson for the current coronavirus pandemic is that these social and environmental forces need to be taken into account when confronting an outbreak, she said.

Epidemics expose the fault lines of our society, and we cannot address them without seeing and trying to mend the fissures in our society, Murray said.

Awareness of the social, cultural and political context of the disease outbreak is an important element in the way the pandemic plays out around the globe, both in terms of how the illness is transmitted and in terms of how it is treated and controlled, noted Paul Farmer, the Kolokotrones University Professor of Global Health and Social Medicine, head of the department of global health and social medicine at HMS, and co-founder of Partners In Health.

We need to look at pathogens, of course, which have different modes of transmission, he said. We also need to understand pathogenic forces that drive transmission in overcrowded hospitals and meat packing plants.

Farmer said that two key takeaways from his decades of experience confronting tuberculosis, HIV, Ebola and other pandemics around the world is that the global medical community needs to understand two deadly concepts: treatment nihilism and containment nihilism.

Treatment nihilism occurs when someone says its not feasible or sustainable to treat someone for a particular disease, typically people who are poor or in rural areas facing complex diseases, Farmer said. It explains why so many Ebola treatment units did not offer any treatment for people with Ebola in the 2014-2016 outbreak in West Africa. Containment nihilism is when someone says its too challenging or too late to control the spread of a disease.

COVID-19 case studies from China, Italy and South Africa highlighted during the symposium demonstrated the critical importance of ramping up treatment capacity while also controlling the transmission of the disease through social distancing, mask wearing and eliminating large gatherings.

In the COVID-19 pandemic in the United States, however, Farmer said there have been early and ongoing declarations from government leaders at the local and national level that it was too late or too challenging to contain the disease or do contact tracing.

This was a key element in the substantial failure at disease control in the U.S., he said.

In April, people had already given up on contact tracing, Farmer said.

At that time, Partners In Health was contracted by the Commonwealth of Massachusetts to provide assistance with contact tracing and social support to help individuals who were exposed or infected and were in isolation or quarantine.

Farmer said he believed that the expanded contact tracing effort Harvard and PIH were able to support likely played a role in helping Massachusetts maintain infection rates at lower levels than in many other states which were experiencing a rise in infection rates.

With COVID-19 now hitting the White House, Farmer said, there is no sign of any contact tracing being done to follow the spread of the outbreak into the communities of Washington, D.C., and beyond.

This is a real problem, since experience has shown us that contact tracing should play a role in curbing the pandemic, Farmer said.

Nanshan Zhong, professor of respiratory medicine at Guangzhou Medical University and director of the Chinese National Clinical Research Center for Respiratory Disease, was introduced by Daley as the legendary physician-scientist who discovered the first SARS virus and who has led the Chinese response to both SARS and SARS-CoV-2.

Zhong detailed the early response and evolving dynamics of the infection in China, describing the rapid recognition, characterization and response to the novel coronavirus when it first emerged in Wuhan.

The first cluster of pneumonia was reported Dec. 27, 2019, and by early January 2020, Chinese scientists had already sequenced the genome of the virus, sharing the information with the World Health Organization by Jan. 12, he said.

Following a rapid, thorough investigation of the outbreak, Zhong said the team on the ground in Wuhan reported definite human-to-human transmission and confirmed, within weeks of the first known cases, that medical staff there had been infected while treating people with the virus.

By Jan. 23, Wuhan was under lockdown; the government was providing real time announcements of the number of patients affected, and it was implementing a program of early diagnosis, early isolation and early treatment.

The Chinese government also issued orders for compulsory social distancing, mask wearing and travel restrictions in an effort to quickly contain the disease, he said, and it swiftly constructed 16 hospitals within 19 days that added 13,000 hospital beds to the local capacity, rapidly filling 12,000 of those beds.

That speedy response to contain and treat the disease helped drive a prompt decrease in cases, he said. Within two weeks of the shutdown order, Zhong said, the outbreak reached its peak. Within four weeks, he said, the outbreak was basically under control.

Since then, the outbreak has remained quite stable inside China, with low levels of infection, Zhong said. The total number of reported cases in China was 80,000 by March 1 and was just over 91,000 as of Oct. 5. The 11,000 cases reported since March 1 includes 3,000 cases brought into China by visitors from outside the country, Zhong said.

Because of the countrys swift, coordinated action, China was able to reduce infections and illness and reopen the economy sooner, Zhong said. Going forward, he added, a strategy of prevention remains crucial until vaccines can be brought online.

Herd immunity through natural infection would likely result in 30 million additional deaths, he noted. Meanwhile, even with a dozen vaccines already in various phases of the clinical trial process around the world, it will likely take 1-2 years, even with global collaboration, for vaccines to be widely available to the general public, he said.

Strong, coordinated action by central governments to help block transmission routes at the community level is still the most effective means for disease control, Zhong said.

There is also an urgent need for close international collaboration in tracing sources of new outbreaks, developing targeted treatment and finding effective vaccines, he said.

Salim Abdool Karim, professor of global health at Columbia University Mailman School of Public Health and adjunct professor of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health, said that, to date, Africa has seen many fewer cases and deaths from COVID-19 than expected, with 1.5 million cases and 36,000 deaths for the entire continent.

So far, the disease has been particularly concentrated in just a few African countries. South Africa alone represents nearly 40 percent of cases, with five nations on the continent accounting for two-thirds of all cases in Africa, he said,

He noted that while many African countries lack sufficient testing and reporting capabilities to gain a completely accurate picture of the spread of the virus on the continent, hospital surveillance confirms that there has not been a great increase in severe cases of respiratory disease there.

There is still no definitive evidence to explain why Africa has been less severely impacted than other regions, he said, but Karim noted that many suspect it may be related to Africas youth dividend, referring to the fact that Africa has a much younger population on average than other places that have seen higher rates of infection and severe disease.

Other possible explanations include the fact that there seem to have been few initial cases seeded before international and local travel were limited by early lockdowns, said Karim, a member of the Africa Task Force for Novel Coronavirus of the Africa Centers for Disease Control and Prevention.

He also noted that there has been a strong, consistent commitment among the nations of the African union to control the outbreak, with strong guidance and a coordinated response led by the recently created Africa CDC. That included bulk procurement of testing supplies and personal protective equipment and early adoption of mask wearing and social distancing.

South Africa had some of the first reported cases on the continent in early March, but instead of seeing a rapid spike, the country was able to quickly get the outbreak under control following a rapid declaration of a national state of disaster and a highly restrictive shutdown, he said.

The early flattening of the curve brought a great deal of economic hardship, according to Karim, but the rapid shutdown bought the health system the time that it needed before cases surged.

If the peak had occurred in April, we would have had lots of death because we were simply not prepared, Karim said. Pushing the peak back allowed us to prepare.

South African health officials opened field hospitals with hundreds of ICU beds, and the government redirected industrial oxygen to medical purposes. Building on experience from nations that faced the surge earlier, physicians there replaced mechanical ventilation with less invasive means of delivering oxygen to patients in respiratory distress.

One important element of African efforts to control spread of the virus was a shift of responsibility from government control to individual engagement, Karim said.

We knew he had to pivot away from government action quickly so that people could take agency, he said.

The early emphasis on shutdowns and travel restrictions was replaced with an emphasis on mask wearing, social distance and hand hygiene. Education and awareness efforts focused on the individuals shared responsibility to their fellow community members.

The message was, If you don't follow the rules, you put everyone at risk, Karim said, drawing on the concept of ubuntu, a paradigm and social norm instilled by former South African President Nelson Mandela in much of South African society, Karim said.

Ubuntu holds I am safe, because you are safe, he said.

Our collective interdependence is the basis on which we will protect ourselves going forward, he said.

One other key concept is perseverance, he said. With the relaxation of restrictions, the levels of infection have begun to climb slowly, but Karim emphasized that the countrys efforts will not be over even when COVID-19 is under control.

Were not looking at it as a sprint, as we did in March, he said. Now were looking at it as a marathon.

We've seen other epidemics, and we will see more, he said. We recognize that we're going to have to deal with this for a long time. This is not something that is just going to go away.

Fabio Ciceri,scientific director of the San Raffaele Scientific Institute and professor of hematology at Vita-Salute San Raffaele University in Milan, shared his insights from the early days of the pandemic in northern Italy and its evolving nature there today.

When COVID-19 hit northern Italy, the novel coronavirus was still almost completely unknown, he said.

We were the first country in Europe touched by the wave, Ciceri said.

Centrally coordinated regional and national responses helped get the outbreak under control relatively rapidly, he said, with national shutdowns and care coordination that focused 80 percent of national health care resources on beating back the novel coronavirus.

Even in the early days of the outbreak, Ciceri said, his team made an extra effort to collect biological samples and clinical data to be used for important research activities, with scientists carefully analyzing the results of numerous potential treatments and enrolling many patients in clinical trials.

These early efforts to incorporate research into care delivery are now providing Italys scientists with the raw materials necessary to power biological studies of the viruss pathology and detail the immune systems response to the infection. Ciceri said this approach helped Italy rapidly lower mortality rates in the early surge.

As clinicians developed new protocols for rapid, aggressive early intervention in potentially serious cases, fewer patients needed to be admitted to hospitals, fewer of those who were admitted needed intensive care, and fewer patients died, he said. Mortality rates for those admitted dropped from 25 percent to 2 percent, he said.

Going forward, Italy has increased early testing and contact tracing of new positive cases and built connections between hospitals across the country to share experience and care, focusing on early interventions for patients with symptomatic disease and referrals to special COVID-19 hubs for patients who might benefit from new treatments and investigational trials.

Daley said the advance warning and the generous flow of clinical and scientific knowledge from colleagues in China and northern Italy was of incalculable value.

They provided us with ample warning about the hurricane headed our way, enabling us here in New England to prepare for the surge and avert catastrophic overload of our hospital systems, Daley said.

Unfortunately, he said, the U.S. failed to mount a coordinated national effort and some parts of our country did not heed the early warnings from abroadchoosing instead to ignore the very public health measures that had worked to ultimately bring the explosive virus under control in the early epicenters of the pandemic. To this day the U.S. continues to struggle to contain the virus, and the death toll continues to mount.

Go here to see the original:

Exposing the Fault Lines - Harvard Medical School

Op-Ed: How Black people maintain hope and why that’s so important – Los Angeles Times

Well, here we are again. With the most consequential presidential election in modern times approaching faster than anybody wants it to, and with the richest and most powerful country in the world threatening to collapse under the weight of its worst and most undemocratic impulses, Black peoples reenergized fight for equality could potentially pull America back from the abyss.

In the midst of moral chaos, the fight to validate Black lives once again requires the nation to examine its own ideals in order to definitively answer the age-old question: What kind of a country are we?

Not so long ago we had a stock answer: We are a country that stands for truth, justice and the pursuit of liberty for all. All political parties Democratic, Republican, Libertarian claimed these principles as their guiding lights; not to embrace them was heresy, or at least political suicide. Of course there were always huge gaps between the stated goals and reality, and Black people have lived in those gaps for all of our time in this country. Still, the broad public agreement on the importance of the ideals meant something actually, its meant everything.

Black people have hope only because of these ideals, because of the ongoing possibility that they might be fulfilled. Its an incredibly tenuous thing to hang a whole future on, but we do it, generation after generation.

We do it understanding that hope is not calm or static. Hope is vigilance, and it is also fury. You have to have hope for a just America in order to feel betrayed by the unjust one. It is a keen sense of betrayal (not nihilism, as conservatives claim) that has been animating this years street protests and calls for police reform. Black hope today is less patient. In 2020, the demand is that the long arc of the moral universe bend now.

Since May, many white people who have joined the police protests and adopted antiracist views have embraced that impatience as their own, as American. But can they really move an unjust system off its foundation?

For many whites, the ideals of democracy are noble and essential so long as the caste system is not seriously disrupted. This was Howard Zinns point in A Peoples History of the United States, that real revolution is almost never successful because the American hierarchy, built on color first and wealth second, is too entrenched, too beneficial to too many to be easily dismantled. In Zinns view, its the hierarchy, not the journey to justice, that largely defines us.

I think very uneasily about the 40-odd percent of Americans unnervingly loyal to President Trump. Its abundantly clear at this point that he is the total antithesis of anything resembling American ideals, the worst white man out there and his followers dont care! Their ideal America has nothing to do with equality and justice for all, and theyre fine with that. Theyre even proud of it.

Trumps role has been to make acceptable a pride in inequality that since the 1960s has had to be kept secret. Now it is cheered at televised rallies, where attendees boo protesters as unpatriotic and stand up for the Confederacy like a wronged family member.

This is what terrifies anyone not in the Trump camp, that these other white people will not be moved or shamed by appeals of change and justice, or worse, that these 40-percenters are, objectively speaking, the real Americans.

Its easy to condemn Trump for dragging down the country, but there would be no Donald Trump were it not for these 40-percenters who have always been open to his message. His naked white fury is a projection of them, not the other way around, and they like what they see.

What can we do about this America? Thats the real question thats been hanging over the country the last four years, the one that must be answered. The strategy of conscientious white folks seems to be simply trying to appeal to everybodys better angels, which Democrats essentially did during their convention in August. Its a strategy doomed to fail. You can be antiracist all day long, but if you cant call out other white folk for their racism because theyre friends or family, or because you think they actually have a point then little will change.

As usual, Black people saw it all coming, from 40,000 feet up, saw it the heady moment Barack Obama got elected the first time, when Republicans declared in the aftermath of the inauguration, before Obama had done anything of note, that their goal would be to make him a one-term president. Anti-Obama-ism a code for anti-Blackness quickly took root and in eight years totally remade the Republican Party, or revealed what it always was.

It was in this shift that Trump found his footing, and the new GOP base found a figurehead. Black people understand that at any given time in history, a good percentage of white people are wedded to anti-Blackness, in one way or another; we always hoped that the percentage in the body politic, like a viral load, would stay below a certain number.

Today, the percentage has hit a dangerous level. The best-case scenario is that the percentage of fair-minded white people and fair-minded people of all colors has risen at the same rate, and that their numbers are enough to soundly defeat Trump at the polls in November.

Even if this is case, the way forward will not be easy. A brewing clash of ideals has already turned violent with the appearance of armed white militias helping the police quell protests and defending property from alleged rioters, with Trump not so subtly urging them on.

At the heart of this latest battle of Who We Are, still at the bottom of the hierarchy but leading the elusive way forward, are Black people and their quest for the country of ideals that America must be. This time the quest isnt symbolic or abstract, or largely limited to Black folks; we all need to finally get there.

Erin Aubry Kaplan is a contributing writer to Opinion.

Read the original post:

Op-Ed: How Black people maintain hope and why that's so important - Los Angeles Times

Hear Wreck and Reference Side Project Hand Model’s Biting New Industrial Song – Revolver Magazine

Over 11 years, seven releases and numerous collaborations with everyone from How to Dress Well and La Dispute to fine art photographer Wolfgang Tillmans L.A. duo Wreck and Reference have established themselves as a force to be reckoned with in the world of experimental metal. Enter hand model, the solo project of the group's Ignat Frege, who contributed production, acoustic drums and vocals to Wreck and Reference's twisted, abrasive soundscapes. Due out October 9th on Bandcamp, the project's debut LP, manufactured joy, explores similar ground as Frege's main band, but with the instrumentals pushed into what he calls a "kinda maximalist" frame. Today (October 7th), hand model have teamed with Revolver to unleash "American Brain Worms," one of the album's most punishing cuts. Blast it below.

Frege comments of the track: "The awful contradictions that pervade life in America. The nihilism, the sadism, the ambivalence. Always chasing the imaginary."

The rest is here:

Hear Wreck and Reference Side Project Hand Model's Biting New Industrial Song - Revolver Magazine

Inflection Point? How Much Change Are We Really Facing? – JD Supra

I am trying to figure out how much I care, as a businessman (as opposed to an actual living, breathing human being), about the chaos swirling around us. Every days news seems more the stuff of a dramatic conceit of someones next thriller than reality. Throw in a car chase and some sex, and weve got a movie. (The North Carolina sexting scandal doesnt really get us there for this purpose.)

I watched the whole Presidential Debate the other week (I passed on watching the warm bucket of spit (bowdlerized version) debate this past week). The debate made me feel like Malcolm McDonald in A Clockwork Orange. You know the scene; eyelids pinned back, forced to watch a re-education video over and over again; it still gives me nightmares. Ugh! Between a truly ugly and chaotic election, war, insurrection, sedition, plague, fire, storms, flooding, locusts (and, ugh, lantern flies), grotesque incivility, and the collapse of norms, where are we going? What next? Human sacrifice and dogs lying down with cats? Terrific.

Talking heads like to talk inflection points because hey, drama sells. The SNL headline from years ago that Generalissimo Francisco Franco Is Still Dead is pretty thin stuff for the 6 oclock news hour. So, we bloviate and bloviate about the fraught state of the world. This is the stuff that very serious people (we know that they are serious people, because they tell us how very serious they are all the time) pontificate, hand wring and generally tut-tut about every day.

Uncertainty makes this easy. Questions about the state of the world and the state of business abound. Asking questions designed to be without answers, fans the flames of anxiety, which of course garners ratings which is probably the point.

I will, for the moment, put aside geopolitical adventurism, space aliens and the possibility that the New York Giants might actually win a football game. You know, the truly unlikely, and focus instead on the election and COVID-19.

Every day we hear: Who will win the election? Is it a blue wave? Do we care? Does the business year effectively end on November 4 if we have no clear winners? What happens if we dont know whose hands are on the levers of power for a considerable period of time? What happens when, no matter who prevails, half the country is convinced that the process was flawed and unfair? Constitutional crisis in the making? Electoral college collapse? Whats the consequence of a new sheriff in town at Justice, at Treasury, at the CFPB, at HUD? What will the Fed do? Is it still really independent? Will we have 104 senators soon? Eleven members of the Supreme Court? Will we really have a green revolution? Is the oil business toast? Is trade policy and in general the countrys geopolitical posture going to change radically (again)? What sort of recession are we really in? Did we come out and were going back? Are we actually in one at all? Has the US economys capacity to grow been secularly reduced? How about the worlds?

Will political and social norms continue to erode, and does that mean that the political pendulum will swing even more wildly between left and right as Democrats replace Republicans and Republicans replace Democrats? What happens if the customary progression of somewhat left of center and somewhat right of center collapses? Is there a chance the Republican alternative has been so badly scrambled by the past four years that we may see a semi-permanent one-party government for a considerable period of time? What will that mean for us all?

Will this plague ever end? Might there be a next one (lets face it, there surely will be, but when)? Will COVID-19 get worse? Are we in the middle of a second wave right now? Does the election matter for how we respond? Is a vaccine more likely to show up after a blue wave? Are major cities likely to reopen sooner after a blue wave? Or not? Should we expect sustainedsocial unrest; a never-ending 1968?

Will we ever return to a semblance of the time before?

If you are inclined to worry about these sorts of things, no matter how finely you grind, you will find more to confound. This is an anxiety fractal.

I take some comfort (again, with my businesspersons hat screwed tightly on) that continuity is more common than discontinuity. Inertia, habit, routine, convention, capitulation, and indeed human nature in general all argue that incremental change is easier and hence more to be expected than rapid or discontinuous change. A rift or abyss from what was to what is, is a rare thing in history.

What will that likely mean for us in 2021? Im expecting a blue wave. Thats certainly the consensus view, though 2016 should give us a hardy dose of humility in the election predicting business. Yet, my guess is that this election drama will not wildly change how our polity is organized, how our country is governed, or how our economy works. It will not radically change the shape of 2021. Sure the arc of many of these things which make up the American experience, which define how the American capital markets function, may change a bit, but while they may be nudged onto a slightly different orbit, they will not be radically reimagined. Taxes will likely go up, but not become confiscatory. Business interest will continue to be deductible. In general, the US Tax Code as it applies to commercial real estate and capital formation will remain largely as it is right now (with the exception of carried interest, the elimination of which is, of course, a democratic shibboleth). The laws affecting capital formation will be essentially unchanged. Corporate law will not radically change. Stakeholders will not be elevated to shareholders, at least formally in most states (though Im watching California, Oregon and Washington, the capital of the woke). The partnership code will not change. The rules governing forbearance, foreclosure and enforcement of remedies, will re-stabilize in pre-COVID-19 form. We will still have the opportunity to play with opportunity zones. 1031? Maybe (a lot of big Biden donors own a lot of real estate).

Capital formation will continue apace, lending and borrowing will progress largely as before. The basics fundaments of our largely capital system will not change radically but might become a bit more mixed la our European friends. After this curious recession is done, GDP will continue to repair (albeit probably more slowly than we would like). The Fed will continue to be accommodative. Many of our friends and colleagues will undoubtedly spend more quality time on Capitol Hill with the various and sundry select committees, but, notwithstanding the continued weaponization of statutes affecting business, I am not predicting that orange jumpsuit will become the new white cuff and collar of Wall Street.

Will animal spirits survive? Probably.

But of course, that all might not all be true.

Are we on the cusp of a chasm where what follows will be radically different than what was? After the current caesura, will we discover that 2021 will be radically different than 2019?

Thats really the question, isnt it? In some ways, while it matters why we might confront discontinuity (is it a geopolitical event, political upheaval at home, more bad medical news, space aliens, or something else?) the big predicate question for planning purposes is whether any of these Four Horseman of the Apocalypse will ride into town at all.

I have always been fascinated with discontinuities. Think about the years leading up to 1914 and the years that followed the War. The world radically changed and strikingly, once radical change began to occur, it seemed to metastasize. Start with a war with millions dead, boundaries scrambled, empires fallen. Arguably enough change for a lifetime but look what else happened. The voting franchise was expanded, prohibition (Good Lord), rapid acceleration of technology in transportation and electronics, radio and the movies, the explosion of the consumer society, the expiation of the gold standard (well, until the British in a fit of moronic sentimentality about their lost empire, returned to it briefly in 1925), changes in literature, mores and public morals, artistic sensibilities, jazz, nihilism, Wall Street bombings (a tad more challenging than recent sit-ins ), radicalism of all sorts including the rejection of new found democracy in much of the developed world, (think Italy) . And thats just some of the change. Looking back, the decade following the war was extraordinarily transformational. While theres not particularly strong causal relationships between war in Europe and much of this, it seems that change is itself an enabler and multiplier of change.

So, as we sit here on what might well be the cusp of something fairly consequential, we should be eyes wide open to the fact that cascading change might be soon our reality.

Theres not really much to do about all that, is there? Unless youve a mind to become a prepper, buy a go-bag, dig a hole, sell your FANG stocks for gold bullion and stockpile MREs, we really have to continue to believe that, in large measure, the past is prelude.

As I sit here, my best bet is that none of the more awful or even more disruptive things that could happen in 2021 will happen in 2021. (As making predictions about the future is particularly fraught, Im comforted by the fact that if massive disruption occurs, no one is likely to have the time or energy to remember this commentary.)

So small-ball change is almost certain and small-ball change is what Im going to prepare for. Im looking at a return to a more regulatory-minded government, more institutionalized hostility toward Wall Street and finance writ large, the probability that the prudentially regulated institutions will be more risk adverse (creating a potential dividend for the alternate lending marketplace).

A reinvigorated CFPB and more focus on protecting consumers will make consumer lending more difficult. Were not done with forbearance, foreclosure bans, rent control and the like, but we will rebalance when it becomes apparent that these threaten to make the delivery of homes to regular people well-nigh impossible. It will be harder to develop both urban and suburban sites. We will all need to recognize and embrace the green agenda. A more redistributive federal policy will obtain. Lots more debt (sometimes I hope that Modern Monetary Theorists are right), and a Fed that will make all that possible will be our reality. Zero bound interest rates for as far as the eye can see. (Lets not even talk about negative rates because I still dont understand them.)

So, I am focusing on getting ready for a sustained period of economic slow or negative growth. If theres economic growth in the United States in the next year or so, it will be uneven. Im expecting to see significant amount of mortgage debt and corporate and industrial debt default. Retail is not coming back. Hospitality episodically. Assets will need to reprice. Values of fixed assets are generally going down and while thats a cyclical change, the cycle may be so long as to be effectively secular. The supply of capital to capital markets will be more volatile as politics continues to intersect with finance and banking in new ways. The alternate or non-bank sector is almost surely to grow in importance. Well see new winners and new losers. And sadly, well see many of our friends and colleagues whipsawed as political toys by our gloriously elected representatives. As I have said so often, it is so easy to blame the financial sector for maladies whose birthing was far away from our world.

So what to do? We will build workout capacity and develop workout strategies and asset repricing strategies and make that part of our practice more robust. Well be prepared to spend a great deal more time with the Bankruptcy Code. Weve dusted off our liquidating trustand securitization structures and thought about how liquidity could be brought to non-performing and sub-performing assets in a difficult environment. Were ready to see loan pools start to trade, either NPL or sub-performing pools. Trades will occur because of asset repricing. Many will become highly motivated sellers because of business or regulatory externalities. Well be alert to how regulated institutions behave and the flow of investable funds into what may be a disproportionately growing alternate lending space. Were watching regulatory change with utmost care. Some of the changes affecting the banking world that had been put on the back burner over the past four years may be re-accelerated into reality. Basil in full, which is almost a certainty if we have a globalist-minded administration next spring. Were trying to think around the corner and see how change will impact markets.

For the moment, stay nimble, my friends. Be mindful that banking and capital formation tend not to be popular during periods of economic stress and as I was saying last week, be ready to protect our industry from real or ginned up assault and calumny. Sticks and stones arent the only things that hurts these days.

See original here:

Inflection Point? How Much Change Are We Really Facing? - JD Supra

Bitcoin battles and jurisdiction under the Defamation Act 2013 – Lexology

A recent decision by the Court of Appeal has clarified when a claimant can bring an action for defamation against a person domiciled outside of the UK.

In the case of Wright v Ver [2020] EWCA Civ 672, the Court considered (1) the proper interpretation and effect of section 9 of the Defamation Act 2013, and (2) whether England and Wales was clearly the most appropriate place for the claimant to bring an action for defamation.

The claimant, Dr Craig Wright, was a prominent computer scientist, Australian national and citizen of Antigua and Barbuda, who moved to the UK in 2015. He famously claims to be Satoshi Nakamoto the creator of the cryptocurrency Bitcoin. However, this was not an issue in the dispute and Nakamotos true identity remains unproven. Roger Ver, the defendant, was the Bitcoin investor and commentator US born, resident in Japan and a citizen of St Kitts and Nevis. Formerly colleagues, Dr Wright and Ver fell out in a disagreement over how to develop Bitcoin. As a result, Ver published a video on YouTube on 15 April 2019, claiming that Dr Wright falsely claimed to be Nakamoto.

Dr Wright commenced an action for defamation against Ver. At first instance, the High Court ruled that England and Wales was not clearly the most appropriate place to bring his action. Dr Wright appealed to the Court of Appeal.

The Court considered section 9 of the Act. Dingemans LJ, in his judgment, considered a number of factors that were relevant in determining whether England and Wales was clearly the most appropriate jurisdiction in which to bring an action for defamation. These factors included:

Based on these factors and the evidence before it, the Court concluded that England and Wales was not clearly the most appropriate jurisdiction for Dr Wright to bring the claim. The YouTube video had been published almost four times more in the US than the UK. Dr Wright had a global reputation, which was just as likely to be affected in other jurisdictions where the publication took place. The question of whether Dr Wright was the inventor of Bitcoin was a global issue. Although Dr Wright claimed that most of his business peers were based in the UK, the evidence indicated strongly that his most important relationships were based in the US. Dr Wright was employed by a UK based company however, that company was part of a multinational group.

This judgment is particularly relevant to individuals who have global reputations. It is not enough for a claimant to claim a tenuous link to England and Wales. It is for precisely this reason that section 9 was enacted. What is clear from this case is that evidence at this early stage is key. Claimants will have to consider carefully whether they can prove a clear link with England and Wales, by taking the factors above into consideration and showing that it is the most appropriate jurisdiction. This is an important strategic question, but also one that is highly fact specific.

In particular, a potential claimant should consider whether a statement has been more impactful inside England and Wales, or elsewhere. Evidence of the statements impact in England and Wales will be critical to the Courts assessment. The reach/readership of the publication, social media reactions, witness statements and media publications are all types of evidence that a claimant ought to collate when making their case.

Read more here:

Bitcoin battles and jurisdiction under the Defamation Act 2013 - Lexology

Hey Max Keiser, Who’s the bigger con? – CoinGeek

In the wake of John McAfees arrest in Spain this week, RT host and alt-finance commentator Max Keiser asked his 234,000+ Twitter followers Whos the bigger con? John McAfee or Craig Wright? Maybe he should look at the ideas hes been selling over the years himself.

Keiser is in the only BTC is Bitcoin camp. He once ran a campaign to become mayor of London, promising to base the citys economy on Bitcoin. Though he touts BTCs infrastructure as an alternative to todays financial system, much of his commentary is on the topic of BTC price (he has at various times predicted $28K, $100K, even $400K per unit).

CoinGeek has a whole article on the raging War on Bitcoin, for background. In it, we can see the motives and whats at stake for those involved.

Unlike Dr. Wright, Keiser is neither a software developer nor a computer scientist with a deep understanding of the technologies he promotes. Though the Maxcoin asset carries his name, he wasnt part of the development team. He is a media personality. His job is to be popular, contrarian, and provocative. It has also involved a lot of digital asset promotion, much of which is about where he sees their prices heading.

The only assets Keiser hasnt ever been particularly bullish about are national fiat currencies. Hes anti-big bank and central banking, and often exhorts his viewers to look at alternatives, such as cryptocurrencies and precious metals.

Maxcoin: His name is on the label

Keiser was/is most famously involved with the Maxcoin projectan altcoin named after himself that launched in 2014. The coin eventually crashed and was rebooted in 2017, and still exists today. Though Keiser has at times been close to and distant from the coins developers, hes still listed as a team member on its current website.

Keisers commentary on Maxcoin also frequently mentioned price increases coming soon. Some of his tweets regarding Maxcoins price in the earlier days appear to have been removed.

For the record, Maxcoins price as of October 7, 2020, is $0.00194569. Tough luck if you were a long-term holder who bought on the advice of Max Keiser.

Heres a chart showing the all-time price history of Maxcoinif it looks familiar, its because almost every altcoin has followed a similar trajectory:

Did Keiser truly believe Maxcoin ran on superior technology, and that its price would go up? Or did he know that, just by saying so on TV, it would generate more buzz and consequently higher prices, at least temporarily?

Maxcoins David Serrano, who says the following history of the coin is just his opinion, gives the following description on the current Maxcoin Project site itself:

Luke & Jordan create and launch Maxcoin. A new alt-coin with fantastic features such as Keccak, Schnorr & KGW. It was widely promoted, and created quite a buzz after the Live launch on the Keiser Report. As you could imagine, the price quickly shot up, but corrected just as hard, leaving many speculators and investors high and dry. With no pre-mine or funds to dig into development, a crowd funding effort was made but unfortunately, after a few unsuccessful attempts, the developers were also left high and dry. Maxcoin was a burning mess of burnt speculators, no funds for future development and a dwindling developers team. Maxcoin as a cryptocurrency may have been ahead of its time with Keccak, Schnorr and KGW, but it was not prepared or backed up for success.

In 2014, Keiser said his portfolio was mostly Bitcoin, but that altcoins offer great ways to gain exposure to different segments of the crypto universe. As I said before, the market as a whole is set for 100x growth so theres plenty of upside.

He was then asked if promoting altcoin investment was ethical, and replied Im like Warren Buffet. I talk about the coins I myself own including Maxcoin.

Keiser has also devoted plenty of airtime in the past to Quark (current price $0.00564) and Startcoin (current price $0.005617).

Keiser is smart enough to know that if he talks about a coin, its price will pump (if only briefly). If, as he said, he talks about the coins he owns, hes increasing the value of his investment by giving it attention.

Keiser has eased off on the altcoin promotion in recent times, probably sensing a shift in regulatory mood post-2017. He has also criticized John McAfee and others who promote the coin of the day scams, as in this particularly prescient post:

In 2019 Keiser switched completely, saying altcoins are finished. Hes gone all-in on BTC and made some more price predictions on BCH and BSV:

Bitcoin Cash, the Roger Ver abomination, is going to ten bucks. Bitcoin Satoshi Vision, from Craig Wright, thats going to ten bucks. Most, or all of these altcoins, are going to pennies, or theyre going to go out of existence, because all of that cash is going to flow to Bitcoin.

Its still all about the price, though. Whether implicitly or explicitly, Keiser is telling his audience what they should and shouldnt invest in.

If Dr. Craig Wright is a conman, hes doing it all wrong

Were not saying Max Keiser has broken any laws. And well assume he declares all his income and pays his taxes. Hes also a lot less reckless than John McAfee. But his attacks on Dr. Craig Wright not only arrive apropos of nothing, its also irresponsible to draw a connection between Wright and paid altcoin promoters.

Dr. Wright does not tell anyone to buy BSV, and he never tells anyone theyll get rich from doing so. In fact, most of his advice is the oppositehe spends most of his media time telling people to build something, and to get out there and work if they want to be rich.

Wrights message has always been that Bitcoin provides the infrastructure, but that even the best infrastructure does nothing by itself. He frequently criticizes speculative trading and HODLing (hoarding Bitcoin in the hope someone else will make the price increase).

Dr. Wright, unlike Max Keiser, has never released a brand new coin. BSV is Bitcoin, traceable all the way back to the Genesis Block of January 2009. Other assets, like BTC and BCH, claim the name Bitcoin and their backers will understandably attack anything claiming legitimacy over theirs. Keiser is a BTC promoter and price pumper, and whether hes paid to do that or whether his gain is simply his own investment, that fact should form the context to any claims he makes about rivals.

Follow CoinGeeks Crypto Crime Cartel series, which delves into the stream of groupsfrom BitMEX to Binance, Bitcoin.com, Blockstream and Ethereumwho have co-opted the digital asset revolution and turned the industry into a minefield for nave (and even experienced) players in the market.

New to Bitcoin? Check out CoinGeeksBitcoin for Beginnerssection, the ultimate resource guide to learn more about Bitcoinas originally envisioned by Satoshi Nakamotoand blockchain.

Follow this link:

Hey Max Keiser, Who's the bigger con? - CoinGeek

Bitcoin Cash (BCH) Closes Last Hour Down $-0.29; Breaks Above 20 Day Average, Price Base in Formation Over Past 14 Days, is Inching Close to 20 Day…

The Hourly View for BCH

Last Updated October 8, 2020, 01:036 GMT

At the time of this writing, BCHs price is down $-0.29 (-0.13%) from the hour prior. The hourly chart shows that BCH has seen 2 straight down hours. As for the trend on the hourly timeframe, we see the clearest trend on the 20 hour timeframe. Of note is that the 50 hour changed directions on BCH; it is now pointing down. The moving averages on the hourly timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

The back and forth price flow continues for Bitcoin Cash, which started today off at 223.15 US dollars, up 1.54% ($3.38) from the previous day. This move happened on lower volume, as yesterdays volume was down 44.28% from the day before and down 24.53% from the same day the week before. Bitcoin Cash outperformed all 7 assets in the Top Cryptos asset class since the previous day. Congrats to its holders! The daily price chart of Bitcoin Cash below illustrates.

Notably, Bitcoin Cash crossed above its 20 day moving average yesterday. Trend traders will want to observe that the strongest trend appears on the 90 day horizon; over that time period, price has been moving down. Also of note is that on a 14 day basis price appears to be forming a base which could the stage for it being a support/resistance level going forward. For another vantage point, consider that Bitcoin Cashs price has gone down 5 of the previous 10 trading days.

For laughs, fights, or genuinely useful information, lets see what the most popular tweets pertaining to Bitcoin Cash for the past day were:

The last time someone asked me my opinion on a crypto chart (had about 75% of their savings in it) was 2017-18 bitcoin cash at about 1500. Told them i thought it would hit mid to low 200s and that I would take my profit and run. He argued all the reasons why i was wrong

The year is 2035: All office jobs are now work from home, with former office buildings being converted into low-rent housing. Every day is another data breach, but everything is public anyway. Your boyfriends toaster gets hit with ransomware. Bitcoin Cash still isnt popular.

@rogerkver @BitcoinCashA yes. Thank you @deadalnix Amaury Sechet and ABC for all the real work you have done and will continue to do for Bitcoin Cash as P2P Digital Cash. And thanks for your efforts too Roger Ver. No one really knows how much youve suffered, do they.

As for a news story related to Bitcoin Cash getting some buzz:

Bitcoin Cash BCH Hard Fork Scheduled For Nov 15, 2020, What you Need To Know?

Once again the community becomes oppose to the consenses between miners and developers, so again hard forking the BCH blockchain and slipping into a new chain will occur to distribute another BCH forked copy to the holders of parent BCH.This hard fork will seem like short benefits to the holders of BCH on the snapshot of Hard fork time.

Go here to see the original:

Bitcoin Cash (BCH) Closes Last Hour Down $-0.29; Breaks Above 20 Day Average, Price Base in Formation Over Past 14 Days, is Inching Close to 20 Day...

What Psychedelic Mushrooms Are Teaching Us About Human Consciousness – Discover Magazine

The scientific world is in the midst of a decade-long psychedelic renaissance. This revolution is expanding our understanding of one of the most captivating scientific puzzles: human consciousness.Numerous research fields are revealing new insights into how psychedelics affect the brain and which neural processes underly consciousness.

Multiple studies testing psychedelic drugs for treating mental illness provide compelling evidence of their therapeutic benefit. Treated disorders have included depression, anxiety, post-traumatic stress disorder, anorexia, obsessive compulsive disorder and addiction. Dozens of clinical trials are underway, the majority investigating the therapeutic effect of psilocybin, the active component in so-called magic mushrooms.This natural compound belongs to the class of serotonergic psychedelics those that activate serotonin (type 2A) receptors.

Researchers are examining the distribution of serotonin 2A receptors to help pinpoint the brain areas affected by psychedelics. The greater the density of these receptors, the greater the likelihood that a particular brain region contributes to the psychedelic experience, according to a study published in Neuropsychopharmacology.Knowing this helps us understand how psychedelics exert their positive therapeutic effect, as well as which brain regions are involved in various states of consciousness.

The claustrum is one of multiple brain regions that is rich in serotonin 2A receptors and organizes brain activity.Cognitive neuroscientist Frederick Barrett and colleagues at the Johns Hopkins Center for Psychedelic and Consciousness Research recently examined how psilocybin affects neural activity in the claustrum.

Published in NeuroImage, their breakthrough study used real-time brain scans in humans to show that psilocybin reduces activity in the claustrum by up to 30 percent. This coincides with people's subjective feelings of ego dissolution and oneness with their environment while under the influence of the drug. The less active the claustrum, the stronger the psychedelic effect reported by participants, including mystical and emotional experiences, and a reduced sense of self.The authors write that the work supports a possible role of the claustrum in the subjective and therapeutic effects of psilocybin.

In this mysterious part of the brain, a thin sheet of neurons sends and receives signals to and from other brain regions. Growing evidence suggests the claustrum orchestrates consciousness gathering, sending and integrating information from almost every brain region. Some, like neuroscientist Christof Koch, believe that the sense of self and ego rest here.

Several years ago, Koch and colleagues of the Allen Brain Institute for Brain Science found anatomical evidence in mice to support this idea. They identified several large neurons projecting from the claustrum, with one wrapping around the circumference of the brain.Around the same time, they published a paper in the Journal of Comparative Neurology describing the vast connections between the claustrum and various brain regions in mice.

Read More: This Is Your Brain On Magic Mushrooms

Barrett says that while the claustrum has received attention as a potential mediator of consciousness as well as psychedelic experience, our current thinking is that the claustrum helps to integrate and orchestrate the coherence of brain networks as they support perception and cognition.

Variations in activity levels of the claustrum are associated with different states of consciousness.For example, the claustrum coordinates synchronized slow-wave activity in the brain. This particular state of consciousness is a feature of certain deep sleep stages during which the brain maintains synapses and consolidates memories. Neuroscientist Yoshihiro Yoshihara and colleagues of the RIKEN Center for Brain Science recently published a compelling study in Nature Neuroscience. They showed in mice that increased neural activity in the claustrum mediates a global silencing of brain activity through resting state slow-waves.

Psilocybin likely subdues the so-called gate-keeper function of the claustrum, causing a loss of organized, constrained brain activity, according to neuroscientists Robin Carhart-Harris and Karl Friston. Such desynchronization increases connectivity between brain regions that are otherwise not engaged with one another, producing a change in consciousness.

Combined with supportive psychotherapy, such expansive, unconstrained cross-talk between brain regions is believed to help break habitual patterns of thinking and behavior, leading to psychological breakthroughs. This mechanism may also explain how psilocybin can affect positive change in such a wide variety of psychiatric conditions. Neuropsychopharmacologist David Nutt and colleagues of the Centre for Psychedelic Research at Imperial College London discuss these ideas in a paper published in Cell.

Though anecdotal, Albert Einstein believed that his most profound scientific breakthroughs happened because he played the violin. He said this practice encouraged communication between different parts of his brain in unique ways that were otherwise inaccessible to his conscious mind. Is it possible that Einstein was describing a state of consciousness invoked by creative pursuits that mimic, albeit to a far lesser extent, the effect of psychedelics in the brain?

Barrett believes that listening to and playing music require a similar presence of mind to deep meditation a connection to the here and now. Barrett says that one of the unique anecdotal effects of psychedelics is said to be complete absorption in the present moment, and to this degree, I do believe that musical experiences can involve similar states of consciousness (albeit to a far lesser extent) to the effects of psychedelics.

Regarding the role of the claustrum, Barrett adds that its function during musical experiences has not yet been studied.Theoretically, this brain structure would be necessary for helping to coordinate brain states during musical experiences. He points out that the claustrum would need to function like a highly controlled orchestra conductor in order to support musical experiences unlike psychedelics, which undermine claustrum activity.If musical experiences and psychedelic experiences both involve the claustrum he says, they may do so in very different ways.

Psychedelic-like experiences and altered states of consciousness can occur in the absence of mind-altering drugs. For example, sensory deprivation is known to trigger hallucinations. In fact, sensory deprivation therapy may help treat some of the same psychological disorders as psychedelic therapy, such as depression and anxiety. Given the claustrums role in integrating multisensory inputs, investigating its function in drug-free, psychedelic-like experiences may answer some intriguing questions in the future.

Barrett suggests that the claustrum probably plays a fundamental, yet different, role in all of these experiences: Lack of sensory input may indeed lead to an imbalance in or disruption of the typical networks and circuits that are involved in claustrum function, however the mechanism by which this might happen is unclear.

While we have yet to crack the code of human consciousness, incremental discoveries from different disciplines may stimulate scientific creativity and enable ongoing progress.Perhaps it is precisely such expansive, unconstrained communication between research areas that will lead us towards the most profound breakthroughs.

Read this article:

What Psychedelic Mushrooms Are Teaching Us About Human Consciousness - Discover Magazine

Psilocybin for depression, MDMA for PTSD: The future of mental health? – Vox.com

Around the world, peoples mental health is in trouble. Even before the pandemic hit, rates of depression and anxiety were rising globally. Now that we also have Covid-19 to contend with, the problem is even more glaring.

Studies show that all the virus-induced losses of life, of jobs, of social connection have come with serious upticks in mental illness worldwide. In the US, for example, the prevalence of depression is four times as high as it was in the second quarter of 2019.

The pandemic has highlighted the inadequacy of our existing tools for coping with these problems. Its not just that a health crisis can easily disrupt access to mental health services, though weve definitely seen that to be true. Its also that drugs like traditional antidepressants are, at best, only a partial solution. While their effectiveness has been hotly contested over the past decade, the evidence now shows that they are more effective than a placebo, but not that much more effective. (Once we account for the placebo response, the effect size of the drugs themselves is modest.) And for some folks who have treatment-resistant depression, the drugs dont work at all.

So if you want to invest in the mental health of people around the world, making us all more resilient to future crises, what can you do?

Believe it or not, your best bet might be to fund drug development for psychedelic-assisted mental health treatments. At least thats the upshot of a new in-depth report by Founders Pledge, an organization that guides entrepreneurs committed to donating a portion of their proceeds to effective charities.

Psilocybin, the active ingredient in magic mushrooms, is being investigated as a potential treatment for depression. Over the past decade, a few studies have investigated the effectiveness of psilocybin for treating depression and end-of-life anxiety in cancer patients, and found that the psychedelic had a surprisingly large effect.

Meanwhile, the drug MDMA (also known as ecstasy) is being studied for use in people with post-traumatic stress disorder. MDMA, which affects serotonin, dopamine, and norepinephrine levels, is best known as a party drug. But research suggests it can also relieve depression and help users access and process memories of emotional trauma. The users in studies participate in psychotherapy sessions where a therapist helps them integrate what they experienced while taking MDMA which often includes increased feelings of empathy and bonding into daily life.

Theres some evidence to suggest that ingesting these substances, in a safe setting and under the supervision of trained therapists, can be more helpful with depression and PTSD than traditional drugs; in some studies, the reported effect sizes for psilocybin, say, are greater than the effect sizes of the current best treatments for depression (though these studies have limitations, so we would need more data to establish this with certainty). Psychedelics might also be helpful for anxiety, addiction, and other issues.

If this seems surprising, its worth noting that medical research into psychedelics has been going on since the late 1800s. In the 1940s and 1950s, psychiatrists used LSD to treat pain, anxiety, and depression. (There are promising preliminary results from studies of LSD for anxiety, though larger controlled studies are needed.) And in the 1970s and 1980s, psychotherapists and psychiatrists administered MDMA to thousands of patients. As psychedelics became popular for recreational use, though, MDMA was banned in 1985 in the US, and the research slowed in many countries.

As Michael Pollan detailed in How to Change Your Mind, research into the therapeutic potential of psychedelic drugs has been undergoing a renaissance over the past decade. These therapies are now gaining traction in some quarters. In Oregon, Measure 109 is on the ballot in November, and if passed, the state will be the first in the US to allow psilocybin therapy to be administered by licensed facilitators.

We still need a lot more research on these treatments, though and one of the benefits of funding the drug development process is that that process will involve doing high-quality studies to prove efficacy and safety. We also need organizations willing to do the hard work of getting a drug approved for medical use nationwide.

The Usona Institute is one such organization that the Founders Pledge report highlights. Its currently working on drug development for psilocybin as a depression treatment in the US, and its already got a preliminary Breakthrough Therapy Designation from the FDA. Thats an acknowledgment that the FDA thinks the early evidence shows psilocybin may have an advantage over available therapy, and it means the FDA offers Usona intensive guidance on its drug development so that it may gain expedited approval. Founders Pledge thinks Usona will put your dollars to better use than any other organization in this space. If interested, you can donate here.

A close runner-up is the Multidisciplinary Association for Psychedelic Studies, which is carrying out drug development for MDMA-assisted psychotherapy for PTSD in the US, Canada, Israel, and soon Europe. If interested, you can donate here. This treatment is already in phase 3 trials, which means approval of MDMA as a therapy could be granted in these countries in a few years.

But the large-scale rollout of new drugs takes a long time. Founders Pledge estimates that for MDMA, itll take six to nine years, while for psilocybin the timeline will be more like eight to 11 years.

Investing in causes that may have a big positive impact in the long term is a wise thing to do. But during a pandemic, some people will want to relieve the suffering they see happening right now.

The psychedelics drug development wont be done for years. So in terms of having an impact now, thats not the way to go, Aidan Goth, who co-wrote the Founders Pledge report, told me.

He emphasized, though, that investing in global mental health during the pandemic is a worthy cause. Mental illness can feed into physical illness, and in itself may cause as much suffering as physical illness in some cases. It can also harm peoples ability to hold a job or care for their dependents. Plus, we should not fall prey to the misconception that mental health is a so-called first-world problem.

Weve looked at the burden of mental health globally, and it is a really, really big problem in lower- and middle-income countries as well. Its not true that its just affecting people in high-income countries, Goth said.

If youre itching to improve peoples mental health while the pandemic is in full swing, youd do well to invest in a project that gives you an immediate return on your investment. For that purpose, Founders Pledge recommends a couple of organizations: StrongMinds and Action for Happiness.

Theres a serious lack of mental health professionals in many developing countries in Africa. StrongMinds, a Uganda-based organization, understood that in order to treat the millions of African women suffering from depression, it would have to train laypeople.

Since its founding in 2013, its scaled up pretty quickly. Lay facilitators have led group talk therapy sessions reaching a total of 70,000 women. Over a 12-week period, the women learn to identify the triggers of their depression and devise strategies to overcome them.

As demonstrated in two randomized controlled trials, this is a powerful and cost-effective intervention, Founders Pledge researchers say. They estimate that StrongMinds prevents the equivalent of one year of severe major depressive disorder for a woman at a cost of around $248 a pretty good deal, especially when you consider this helps the woman as well as her dependents.

StrongMinds says it is uniquely positioned to meet the demand for depression treatment in sub-Saharan Africa during the pandemic. Its offering teletherapy, a chatbot, and other treatment approaches in line with social distancing requirements.

Like StrongMinds, Action for Happiness brings people together in small groups and its run by volunteers in each local community. But this one is a UK-based organization that mostly operates in Europe, though its also reached countries like the US and Australia.

Action for Happiness provides eight-week courses, called Exploring What Matters, where participants talk through strategies for crafting a happier life, such as developing a mindfulness practice. The course has been shown to improve subjective well-being, with reductions in depression and anxiety and increases in happiness and life satisfaction. Based on a randomized controlled trial, Founders Pledge found this program to be extremely cost-effective, with high potential for scale-up.

During the pandemic, Action for Happiness has gone from in-person courses to virtual ones, launching a free online coaching program to improve wellbeing.

Given that Founders Pledge evaluated StrongMinds and Action for Happiness before the pandemic, you might wonder whether these organizations are still helping people cost-effectively now that theyve had to shift from an in-person to an online methodology.

Goth explained that when Founders Pledge researchers evaluate an organization, they examine not only the specific programs its running but also the organization as a whole whether its leadership is strong and whether its management can be trusted to competently carry out its mission. So the researchers still believe in StrongMinds and Action for Happinesss ability to serve people effectively now.

We trust that theyre well-run and we think theyre doing good work given the circumstances, Goth said. Theyre the best were aware of.

If this cause speaks to you, you can donate to StrongMinds here or donate to Action for Happiness here.

Sign up for the Future Perfect newsletter. Twice a week, youll get a roundup of ideas and solutions for tackling our biggest challenges: improving public health, decreasing human and animal suffering, easing catastrophic risks, and to put it simply getting better at doing good.

Help keep Vox free for all

Millions turn to Vox each month to understand whats happening in the news, from the coronavirus crisis to a racial reckoning to what is, quite possibly, the most consequential presidential election of our lifetimes. Our mission has never been more vital than it is in this moment: to empower you through understanding. But our distinctive brand of explanatory journalism takes resources. Even when the economy and the news advertising market recovers, your support will be a critical part of sustaining our resource-intensive work. If you have already contributed, thank you. If you havent, please consider helping everyone make sense of an increasingly chaotic world: Contribute today from as little as $3.

See the original post here:

Psilocybin for depression, MDMA for PTSD: The future of mental health? - Vox.com

Thanks to the Shroom Boom, This Small Stock Could Soar – InvestorPlace

Oftentimes, the best way to score enormous returns in the stock market is by buying leading stocks in emerging megatrends before those megatrends go mainstream.

Thats why you should consider buying psychedelic stocks today.

Arguably the most defining pharmaceutical megatrend of the 2020s will be what we like to call the Shroom Boom or the mass de-stigmatization, legalization and utilization of psychedelic-inspired medicines for the treatment of various mental health disorders.

Antiquated beliefs that psychedelics like magic mushrooms and MDMA are bad for you are being thrown out the window, and replaced by a wave of academic research which shows that the active ingredients in these psychedelics can actually provide meaningful benefits for patients suffering from depression, anxiety, anorexia, addiction, etc.

Over the past few months, the Shroom Boom has started to go mainstream.

Multiple Netflix documentaries like Have a Good Trip: Adventure in Psychedelics and The Business of Drugs have shone a favorable light on psychedelics in 2020.

Last month, UC Berkeley launched a new center for psychedelic science and education, with its media relations department saying in a press release:

Fifty years after political and cultural winds slammed shut the doors on psychedelic research, UC Berkeley is making up for lost time by launching the campuss first center for psychedelic science and public education.

Last week, widely followed Freakonomics did a podcast on psychedelic-inspired medicines.

Also last week, Joe Rogan the king of podcasts highlighted psychedelics in a segment.

The barriers are being broken. It has started. The Shroom Boom is going mainstream.

This is a $30+ BILLION market in the making and multiple stocks will score 1,000%-plus returns over the next decade as this market disrupts the mental health treatment status quo.

There is a small-cap stock that is pioneering a new era of psychedelic-inspired medicines. Like others in the sector, it could soar by much more than 1,000% over the next few years.

A few months ago, MindMed (OTC:MMEDF) was the most established public company pushing forward on psychedelic-inspired medicines.

I say at the time because thats no longer true.

In mid-September, the true leader of the Shroom Boom COMPASS Pathways (NASDAQ:CMPS) finally came public via an IPO that was a huge success.

For a few reasons, COMPASS Pathways is the unrivaled leader in psychedelic-inspired medicine commercialization and, by extension, the best bet on the Shroom Boom.

First, the company has a leading, proprietary psychedelic treatment that is already going through clinical trials.

COMPASS is hyper-focused on using the active ingredients in magic mushrooms something called psilocybin to treat treatment-resistant depression, or TRD.

The company has created a proprietary psilocybin formulation dubbed COMP360 which completed Phase 1 trials in 2019, in which the treatment was shown to be well-tolerated. Phase 2 trials have commenced in 2020. Results are expected in late 2021.

Importantly, this timeline puts COMPASS miles ahead of everyone else in this space. Most of COMPASSs peers are in the experimentation phase, still trying to come up with their own proprietary psychedelic-inspired medicines meanwhile, COMPASS is in the midst of clinical trials.

Second, COMPASSs board includes some of the pharma industrys brightest stars, and its early backers include some of the worlds most well-respected VCs.

The former Chairman of Johnson & Johnson sits on COMPASSs board. So does the former Director of the US National Institute of Mental Health. And the former executive director of the EMA. The board also counts leading psychiatry professors from Stanford, Harvard, and Imperial College London as members.

As if that roster werent enough, legendary VC investor Peter Thiel best known as Facebooks first investor also owns a 7.5% stake in COMPASS.

So if anyone is going to crack the code of making a best-in-market psilocybin treatment for depression its going to be these guys.

Third, the company has a clear pathway to being first-to-market and first movers advantage matters in the Shroom Boom.

Because COMP360 is already in Phase 2 trials and because the team here knows a thing or two about commercializing therapeutics, COMPASS has a clear pathway to being first-to-market with an FDA-approved psychedelics-inspired treatment.

Thats a big deal, because FDA approval takes a long time, meaning that COMPASS will likely have a two- to three-year window in the 2020s in which COMP360 will be the only psych treatment out there a period long enough for COMPASS to establish dominance in the market.

How big is this market?

Well, the global anxiety and depression treatment market measures somewhere around $20 billion. Plus, COMPASS can leverage its psilocybin treatment to address other markets like addiction and ADHD, which together comprise a $12 billion treatment market.

So, youre talking a total addressable market north of $30 billion.

COMPASS projects as the leader in that market.

Is 20% market share doable? Absolutely. That would put COMPASS annual sales at $6 billion.

Pharma stocks today fetch around a 5-times sales multiple. That implies a potential future market cap for COMPASS of $30 BILLION.

The companys current market today is $1.2 billion.

Not many stocks out there have a realistic chance to rise 30X over the next several years COMPASS is one of them and for that reason alone, this stock should be on your radar today.

On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.

The New Daily 10X Stock Report: 98.7% Accuracy Gains Up to 466.78%.InvestorPlaces brand-new and highly controversial newsletter is rocking the industry delivering one breakthrough stock recommendation each and every trading day delivered straight to your inbox. 98.7% Accuracy to Date Gains Up to 466.78%. Now for a limited time you can get in for just $19.Click here to find out how.

Continued here:

Thanks to the Shroom Boom, This Small Stock Could Soar - InvestorPlace

5 Reasons I Switched To The Psychedelic Business – Green Entrepreneur

October7, 20205 min read

Opinions expressed by Entrepreneur contributors are their own.

After attending Burning Man in 2018, I decided to leave the cannabis space and create the first psychedelic wellness brand, Delic. My partner, Jackee Stang, and I are seasoned executives in the cannabis space, but we felt it was time to transition and use the lessons learned in cannabis and apply them to the emerging psychedelic space. Burning Man, 2018, is when Delic journeyed from fun idea to brick and mortar.

Here are five reasons why I decided to leave cannabis and move to psychedelics.

Psychedelics have always been a part of my adult life, including my professional history. Most notably, my partner and I were both executives at High Times, which originated in the 70s as a place to get people high, not just as a magazine to disseminate information about cannabis.

In my personal experience, psychedelics have done more for my wife in a few years of using them in a clinical setting than 20 years of traditional psychotherapy or SSRIs did for her. My first-hand experience of watching her positive change in anxiety and depression has been extremely motivating to help others achieve the same benefits. My love for the plants and the potential value they can bring to our society has turned into a deep passion for educating people and helped destigmatize and normalize the substances.

If we look at the state of the Universe, it is quite remarkable that humans exist in the first place and can communicate and love one another. Despite the cosmic beauty of our existence and the amazing things that happen in the world every day in front of our eyes, we are stuck in a societal mental health epidemic.

Even beforeCOVID, our society has been living in a mental health epidemic. A person commits suicide every 40 seconds around the globe. Mental health issues like anxiety and depression are pervasive throughout our society, affecting people regardless of age or background. Not only is the issue widespread, but the current treatments are not adequate and oftenonly cover up the symptoms rather than treat the underlying cause.

More university and government-backed studies are looking into the benefits of psychedelic-assisted psychotherapy in the U.S. than studies are looking into cannabis. These studies have had remarkable results for treatment-resistant depression, PTSD, anxiety, and other mental health conditions. The data shows us that the medical and research fields are taking this seriously, which tends to be an early sign of something becoming mainstream and universally accepted.

Related:Psychedelics: The Next Wave For Investors?

Everyone in the US universally agrees with the First Amendment freedoms, but cognitive freedom is not one of those fundamental freedoms. By cognitive freedom, we mean the freedom for individuals to control their consciousness, including psychoactive substances like psychedelics. If we dont have the freedom to control our consciousness, how can we ever truly have freedom of speech?

The caveat to cognitive freedom is we live in a civilized society and need to keep each other safe. To do this, rules, boundaries, limitations, and regulations are sometimes necessary. In cannabis, we saw rapid regulations created mainly by people who didnt understand cannabis or the experience it creates. We want to take this lesson learned and make sure the psychedelic industry doesnt make the same mistake, which is why were proud to be one of the leaders in psychedelic education. We are striving to make sure everyone can have cognitive freedom to maximize safety between all of us.

While some analysts were still predicting a bullish market for cannabis, we became aware that the green bubble was getting ready to burst several years ago, in a similar parallel to the dot com bubble. Cannabis companies had massive losses, advertising and branding dollars werent generating brand awareness, especially in Canada, and high valuations didnt accurately reflect companies performance.

The public markets were dropping with investors losing confidence, and smaller companies felt the strain of the regulatory hurdles and lack of access to standard business services like banking. In our eyes, the next natural step from cannabis was the psychedelic industry, and we wanted to take our lessons learned and apply them to the new market, so we dont make the same mistakes.

When looking at cannabis, were talking about a single plant that can be broken down into over 100 different cannabinoids, each with their own physiological effects and potential medical and health and wellness benefits.

Most people think of psychedelics as only a handful of substances, but the sky is the limit for this unique class of drugs in reality. Within psychedelics, we can look at different categories like tryptamines, phenethylamines, lysergamides, or dissociatives. Each of these distinct categories has dozens of substances and analogs within them. Each of those substances has its unique effect, similar to how every cannabinoid has its outcome.

This market will need to approach regulating many different substances that do other things for different people. It will behoove us to take our time and learn about each substance in various trials and experiments. We are excited to be at the forefront of educating people about all psychedelic substances, not just the popular ones.

Related:Will Cannabis Entrepreneurs Switch To Psychedelics?

See the article here:

5 Reasons I Switched To The Psychedelic Business - Green Entrepreneur

Field Trip Health, Another Psychedelic Therapy Company, Goes Public – Forbes

The cofounders of Toronto-based Field Trip Health. From left to right: Mujeeb Jafferi, Hannan Fleiman, Ryan Yermus, Joseph del Moral, and Ronan Levy.

Welcome to the era of psychedelic stocks. Toronto-based Field Trip Health became the third psychedelic therapy and drug development company to hit the public markets on Tuesday.

Field Trip went public through a direct listing on the Canadian Securities Exchange after it completed a reverse takeover of oil and gas company Newton Energy Corporation.

Ronan Levy, a cofounder and the executive chairman of Field Trip, says psychedelic drugs, which are currently illegal under federal law but show promise in clinical mental health studies, will become the next blockbuster pharmaceutical products.

As you look at psychedelics, these molecules stand poised to fundamentally revolutionize how we consider mental, emotional and behavioral health, says Levy.

Before going public, Field Trip closed a $12 million private placement deal, which brought the total amount it has raised since founding to $20 million. On Tuesday, the stock opened at 3.50 Canadian Dollars and closed at 2.70 Canadian Dollars. After the first day of trading, Field Trips market cap was $102 million.

MindMed, a psychedelic drug development company based in New York, was the first company of its kind to test the public markets in March on Canadas NEO Exchange and the Peter Thiel-backed Compass Pathways, which is pursuing FDA approval for its synthetic version of psilocybin, went public on the Nasdaq in September. Compass Pathways has a market cap of $1.37 billion, while MindMed is approaching $200 million.

Field Trip, which is not profitable and incurred a net loss of $2 million, has a three-pronged approach to the psychedelics markettreatment clinics, drug development, and drug manufacturing.

The company currently operates three ketamine-assisted psychotherapy clinics in Toronto, Los Angeles, and New York. Field Trip plans to scale up to 75 clinics in the next few years, says Levy.

Tripping In Style: Patients receive intramuscular ketamine injections at Field Trip Health's high-end clinics in Los Angeles and New York. Patients are given ketamine lozenges in Toronto.

Patients receiveketamine, a dissociative psychedelic approved by the FDA as a fast-acting anesthetic, at Field Trips clinics off-label to treat anxiety and depression. Ketamine is the only legal psychedelic drug at this moment. The FDA approved Johnson & Johnsonsketamine-derived nasal spray Spravato for suicidal ideation and treatment-resistant depression last year, but Field Trip sells intramuscular ketamine injections in the U.S., which produces a more intense psychedelic experience. (A program of six ketamine injections and 11 therapy sessions costs nearly $5,000. In Canada, the therapy involves ketamine lozenges.)

Field Trips big plan is bring its own hallucinogenic compound to market. Its developing its own novel psychedelic molecule, FT-104, and plans to pursue FDA approval. Field Trip is being tight-lipped about which mental disorder FT-104 will target, but the compound does engage the serotonin 5HT2A receptor in the brain, which is believed to be responsible for psychedelic experiences.

Levy says FT-104 is similar to the chemical structures of known psychedelic substances like psilocybin. Field Trip filed a provisional patent and the company hopes to launch clinical trials by the end of 2021.

The third strategy Field Trip is pursuing is psilocybin cultivation. It partnered with the University of the West Indies in Mona, Jamaica, where psilocybin is legal, to build a magic mushroom research and cultivation facility.

For the time being, Field Trips clinics only offer ketamine-assisted psychotherapy. Eventually, as certain compounds gain FDA approval or become legal through state initiatives, Levy says the companys clinics will expand to other psychedelic therapies. (In Oregon, psilocybin could be legalized for therapeutic use through a ballot measure in November.)

Youll see a robust suite of psychedelic molecules available to people, whether its MDMA, psilocybin, DMT, peyote, or synthetic molecules like FT-104, all of these will be incorporated into our system, says Levy. Through our clinical hubs, well be agnostic as to which molecules we use as long as they lead to the best outcomes for patients.

Field Trip was founded by Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi in April 2019. All of the cofounders except for Jafferi worked together previously in Canadas cannabis industry, where they cofounded medical marijuana companies Canadian Cannabis Clinics and CanvasRx, the later of which was acquired by Aurora Cannabis for $37 million in 2016.

Dieter Weinand, former head of Bayers pharmaceutical division, has joined Field Trip as a member of the board. Over a 30-year career, Weinand worked at Sanofi, Otzuka and Pfizer. Weinand helped bring to market drugs like Liptor and Abilify, which is used to treat schizophrenia, depression and bipolar disorder. Weinand says hes been convinced by the studies coming out of academic institutions including Johns Hopkins and Imperial College London that psychedelic drugs have significant potential in treating mental health disorders.

When you look at people who have major depression or schizophrenia, each time they have an episode there are structural and chemical changes in the brain that become permanent, says Weinand. That has to be reversed somehow and we have nothing right now that changes that. There seems to be clinical evidence that psychedelics can intervene in that progression and potentially reverse these structural changes over time.

Nearly 30% of people with major depression dont respond to current medications, says Weinand. A drug that could help this patient population could be quite significant, he says.

The psychedelic renaissance underway is creating an industry worth around $100 billion, according to a report written by Canaccord Genuity Corp. analyst Tania Gonsalves. From depression to post-traumatic stress disorder, addiction tochronic pain, about one billion people are afflicted by disorders that studies have found could be treated by psychedelic-assisted therapy.

The legal cannabis market, which is expected to hit $19 billion in annual sales this year, has nothing on the hallucinogenic drugs, says Levy.

Psychedelics as an industry is much larger and more significant than cannabis, he says. The way to frame the psychedelic industry is what chunk of the $240 billion U.S. mental health market are psychedelics going to take? I think itll be most of it.

Link:

Field Trip Health, Another Psychedelic Therapy Company, Goes Public - Forbes

Are Psychedelic Drugs Canada the Next Wellness Trend? – The Kit

Would you do a ketamine-assisted therapy session? Ever considered microdosing magic mushrooms? As research mounts on the health benefits of psychedelic drugs like psilocybin, ayahuasca, ketamine and mescalineand government restrictions on them begin to easewere taking a look at whether psychedelics are the next cannabis in our Psychedelics Now series.

Its amazing the difference a few years makes. Remember when cannabis was mostly seen as a seedy street drug that belonged in stoners basements? Now, sleek storefronts sell slickly marketed CBD oils and edibles like fizzy drinks and gourmet chocolates purporting to do everything from improve your sex life to enhance your at-home movie night. So dont be surprised if what comes to mind when you think of psychedelic drugs shifts just as much in the next few years. In cannabiss wake, a movement to decriminalize and perhaps ultimately legalize psychedelic substances such as psilocybin (which is responsible for the psychedelic effect of magic mushrooms), ayahuasca and mescaline is gaining steam in Canadawith the focus, for now, on what they can do for our mental health.

The process is well on its way. In August, federal health minister Patty Hajdu granted four end-of-life patients exemptions from current drug laws to use psilocybin to help deal with the anxieties of their terminal illness. (Fifty-three-year-old Laurie Brooks, who has colon cancer, was one of themread her story next in our Psychedelics Now series). Three more exemptions quickly followed, perhaps a harbinger of restrictions being eased.

We might see an even bigger shift on psychedelics status this fall: The government is currently considering a petition that calls for the decriminalization of psychedelic drugs, which was signed by 15,000 people and sponsored by a Green Party MP; a Liberal MP is also introducing a private members bill that aims to decriminalize possession of small amounts of illicit drugs. These efforts have been strongly supported by the Canadian Psychedelic Association, which aims to usher psychedelics into the mainstream in a conscious and considered way. I feel more strongly than ever that decriminalization will happen, says Trevor Millar, its executive director. Were 10 years ahead of where I thought wed be at this stage of the game five years ago.

An episode of Goop Lab on Netflix showed staffers travelling to Jamaica, where psilocybin is legal, and sampling it on-camera

Perhaps the main reason psychedelics are gaining public acceptance is because of the mounting clinical research showing their effectiveness at treating a range of mental health conditions, from PTSD and addiction to treatment-resistant depression and anxiety. There are studies out of Harvard and NYU, the University of British Columbia and University of Toronto. Johns Hopkins University in Maryland, often credited with kicking off the research renaissance in this area after its 2006 publication on psilocybins safety and long-lasting positive effects, is now studying its effectiveness as a therapy for even more conditions, like Alzheimers disease, anorexia nervosa and chronic Lyme disease.

While widespread acceptance of psychedelics therapeutic potential is fairly recent in North America, substances such as ayahuasca have long been used traditionally in many cultures, often as part of ceremonies guided by shamans. Theres a Western fascination with this practice and a tourism aspect, too: Gwyneth Paltrows wellness-trend-hunting site, Goop, published a travel guide to psychedelic retreats in Peru, Mexico and the Netherlands, and recently an episode of Goop Lab on Netflix showed Goop staffers travelling to Jamaica, where psilocybin is legal, and sampling it on-camera. A Goop endorsement may not necessarily propel the case for psychedelics as either a sacred traditional ritual or an evidence-based mental health aid, but it certainly helps demystify themand thats something advocates are hoping for.

Most people assume that psychedelics are not available because theyre dangerous or addicting and thats fundamentally not the truth, says Dr. Pamela Kryskow, a medical doctor in Vancouver who works in chronic pain, functional medicine and ketamine assisted psychotherapy. All of these substances were available at one point as a medicine and they were moved out of public usage because of racism and political control reasons, not because of danger. Shes referring to the fact that racialized communities are much more heavily penalized and controlled by drug laws, and the political war on drugs that saw to it that promising research on psychedelic medicine that began in the 1950s was halted by the mid 1970s. It has taken decades for psychedelics to rebuild their reputation.

Being the generation that I am, mid Gen X, I had deeply absorbed all of the messaging of the war on drugs, which were messages of fear and control that I took to be true

Kate Browning, a Vancouver psychotherapist and registered nurse who specialized in mental health and substance abuse, knows what it is to be suspicious of psychedelic drugs. I was not interested in psychedelics at all beforebeing the generation that I am, mid Gen X, I had deeply absorbed all of the messaging of the war on drugs, which were messages of fear and control that I took to be true. So I did assume that these substances were dangerous, and when I learned otherwise it was a complete revelation. Now, shes among the many mental health professionals who want to see psychedelic substances widely available for therapeutic use. We know that making things illegal, withholding information about them, increases the danger of them tremendously, she says. I want to see my psychotherapy patients who really need these medicines have them available to them without risk, without stigma, without secrecy and to just to have a higher quality of life.

That quality of life could include not being dependent on medication long-term. The psychiatric medicines that we use right now are considered lifelong, not curative, says Kryskow. We just dont see that with a psychedelic medicine. It might be one, two or three sessions and thats it. In a therapeutic context, a patient would take a dose of a psychedelic substance such as psilocybin or ketamine with a trusted mental health professional who would help guide and support them through an hours-long trip to help them gain new insights or clarity into the emotions or traumas that underlie their issues. Theyd then talk about their experience with the therapist to help integrate those insights into their life.

Psychedelics tend to be a more intense and unpredictable experience than cannabis, so theyre generally less frequently used and have less commercial potential. But cannabis legalization was similarly helped along by the discussion of its wellness benefits, because its easier to argue that people should have access to a drug to help ease their pain or anxiety. Taking a drug for recreational purposes is typically seen as criminalization-worthy, with one notable exception: alcohol. Compared to alcohol, magic mushrooms are far less dangerous by multiple measures on the personal and societal level, says Millar.

While there is still a lot we dont know about psychedelics, the only way to remedy that is with more research, more funding and more openness. Id like to see a very robust research program across the country so that we can figure out what medicine should be used for what reason for what person, says Kryskow. But she and other psychedelics advocates believe these substances are so safe that they should be available for non-medical purposes, too, like personal growth or simply pleasure. I want us to have an adult conversation on how we can use these plants responsibly in our society to be happier, healthier and more creative.

See the original post here:

Are Psychedelic Drugs Canada the Next Wellness Trend? - The Kit

Mandy Nolan’s Soapbox: The Magic of the Mushroom Echonetdaily – Echonetdaily

Science is finally telling us something that a lot of us already knew. Psychedelics are good for us! Mushrooms for mental health! Ah, the healing powers of Mother Earths wonder drug psilocybin! What an incredible world we live in where the best medicines are right at our fingertips! LSD-advocating psychologist, Timothy Leary, had it right after all. Perhaps thats why Nixon thought he was the most dangerous man in America. Tom Robbins called Leary a brave neuronaut for taking steps into psychedelic mind expansion, back in the 1960s.

Back in the 60s the idea of mind expansion wasnt good for business. The last thing anyone wanted back then was people tripping off their nut, getting well, thinking outside the box(wow, you should feel this box, I can hear the colours) and questioning authority. It was when we were busy making lots of lovely pills. Pills that made us quiet. Pills that helped us stay under the line. The system doesnt want you taking substances that make you question its shit! They want to hurry up the sedation! Knock us out. They dont want to turn us on and turn us up. Nope. Numb us. Turn us down. Make us less dangerous. More compliant.

Sixty years ago, Leary, who famously dosed himself a lot, believed that LSD had potential for therapeutic use in psychiatry. We are only just talking about it with seriousness now. Psychedelics scare people. By people, I mean straight people. Its ironic because theyre the people who probably need it the most. It used to be one of my favourite things in my twenties going tripping with a straight person. I just loved watching their mind bend. Better than anything on Netflix.

But research is showing that psychedelic assisted therapy is very effective in treating depression, anxiety and addiction. It is also extremely effective in helping people who suffer with post-traumatic stress disorders. In the US, the treatment is expected to receive regulatory approval by 2021. That bodes well for us. But it needs to happen now. If treatments like these are shown to have such huge success rates, then isnt it cruel or inhumane not to extend them to those suffering, asap?

Perhaps there really is magic in the mushrooms.

Thought leaders in Silicon Valley are mad for micro dosing. Its the way they stay ahead of the creative curve and boost their work performance. In one article, I read that you can pay $2k a month and you get your own psychedelic-trip coach guru to guide you through the windy pathways of your mind. Kind of like a cerebral sherpa. Steve Jobs was rumoured to love the limit-busting power of psychedelics, ribbing his rival Bill Gates for being unimaginative. I mean how much better would Windows have been if Gatesy tripped out! Wed be running Wormholes 10 Zooming our meetings into parallel universes.

Its often the social uses and consequential bad PR of prohibited substances like psychedelics that hinder them being approved for medicinal use. Even if it means lots of people get well, its not good politics. Which seems pretty crazy. You have to be brave to push for change. And if theres one thing our current leaders arent, its brave. Or interesting. Or able to think beyond the next election into that hazy thing on the horizon called a fucking future. Shit, please dose parliament. Lets micro dose Canberra and see if we cant bring on some compassion, some vision and some bloody awesome live streaming when they speak from the floor!

Madame speakerwhy is Mr Morrison curled up in the foetal position?

Hes feeling into the budget.

To find out more about psychedelic assisted therapy and what world leading experts have to say go to mindmedicineaustralia.org

Keeping the community together and the community voice loud and clear is what The Echo is about. More than ever we need your help to keep this voice alive and thriving in the community.

Like all businesses we are struggling to keep food on the table of all our local and hard working journalists, artists, sales, delivery and drudges who keep the news coming out to you both in the newspaper and online. If you can spare a few dollars a week or maybe more we would appreciate all the support you are able to give to keep the voice of independent, local journalism alive.

See the original post:

Mandy Nolan's Soapbox: The Magic of the Mushroom Echonetdaily - Echonetdaily

/REPEAT — New Wave: To Provide Sponsorship for the Documentary "The World on Drugs"/ – PRNewswire

TORONTO, Oct. 13, 2020 /PRNewswire/ -NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR)(FWB: 0XM2) (OTC: TRMND) an investment issuer that provides capital and support services, announced it will provide sponsorship for the next phase of the upcoming Microdose Psychedelic Insights documentary "The World on Drugs", a Bold Commentary On Drug Policy, Psychedelic Medicine & Mental Health.

At this critical intersection of the pandemic, the opioid crisis and the mental health epidemic, the team at New Wave Holdings is proud to sponsor this international effort to shift policy and public opinion surrounding these major public health concerns. The project is aimed at reframing the context of psychedelic medicines and illuminating the radical hope they offer to humankind during this critical juncture of disruption and evolution.

With exclusive content filmed by the Microdose team in Mexico in the first phase of this project, New Wave Holdings is pleased to announce funding for the film to carry this message in the next step of its journey in Vancouver, British Columbia. As new research emerges to reinforce the idea that psychedelic compounds are poised to revolutionize mental healthcare, so are the powerful and compelling stories of the people who have healed from them. With powerful commentary from prominent voices across Mexico, the next step in production of "The World on Drugs" aims to speak with leading experts in Vancouver - another highly relevant location to this discussion.

The team at New Wave Holdings believes in providing robust mental health treatments to the world and that psychedelics hold immense promise for humanity through this crucial moment in our history. They are proud to support the novel efforts by the Microdose team to explore psychedelics and mental health across borders and through a rich, diverse lens. "The World on Drugs" is meant to not simply just inform, but to inspire actionable change and tangible impact. The team at New Wave Holdings is proud to play a direct role in this necessary effort and feels it to be their corporate social responsibility during these trying times.

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTC:TRMND) is an investment issuer focused on the burgeoning psychedelic and esports sectors. In the psychedelic sector, New Wave will focus on supporting research on active psychedelic compounds, creation of consumer products based on functional mushrooms, and developing an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com

ABOUT MICRODOSE PSYCHEDELIC INSIGHTS

Microdose Psychedelic Insightsaims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. They enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. Microdose work with the industry's most influential stakeholders, some of the world's best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.

To request media accreditation, or to arrange interviews with key personnel please contact: Kristina Spionjak / [emailprotected]/ https://microdose.buzz

Information relating Microdose Psychedelic Insight contained in this news release was provided by Microdose Psychedelic Insight and/or its agent and has not been independently verified by the Company. The Company does not take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forwardlooking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forwardlooking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forwardlooking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forwardlooking information. The Company's actual results could differ materially from those anticipated in this forwardlooking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company's strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forwardlooking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forwardlooking information should not be unduly relied upon. Any forwardlooking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forwardlooking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

SOURCE New Wave Holdings Corp.

Original post:

/REPEAT -- New Wave: To Provide Sponsorship for the Documentary "The World on Drugs"/ - PRNewswire

Opening the Door to the New Psychedelics Revolution | 2020-10-09 | Investing News – Stockhouse

For the better part of two years, Stockhouse has been covering the steady growth of the psychedelics market and how the mental health & wellness sector has benefited from the scientific and medical development of so-called magic mushrooms.’ Now, the investment community is beginning to drive capital markets in this space to heights few could’ve imagined even two years ago.

Psilocybin-assisted psychotherapy is currently being widely studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.

Just over a year ago, Stockhouse covered an intriguing forum at the Extraordinary Future Conference in Vancouver, BC entitled: From the Plant Medicine Frontier - How Psychedelics like Psilocybin could upturn the mental health industry.” Keynote speaker and author, pioneering research pharmacognosist, lecturer, and one of the world’s leading authorities into the medicinal properties and mental health benefits of psychedelics, Dr. Dennis McKenna, had this to say:

Psychedelics are unlike any other kind of medicine that’s ever been introduced into biomedicine. Of all the new drugs discovered that eventually make it through clinical trials and eventually becomes available to people, these (psychedelic) drugs are not like them. They can’t be reduced to just another pill’ because they are connected with history and a cultural context and even a co-evolutionary aspect. No one wants to discourage the research on psychedelics and the development of high quality psychedelics for therapeutic uses, but should also not turn our backs on nature.”

Today, massive amounts of capital are entering the psychedelic health & wellness space. And the biggest splash was recently made by Compass Pathways PLC (NASDAQ: CMPS) a U.K. unicorn start-up backed by tech billionaire Peter Thiel and lead investor Christian Angermayer. Labelled as the industry’s most anticipated psychedelic IPO”, Compass became the first psychedelic medical company to go public on a major U.S. exchange. The drug-maker's shares promptly rose by an eye-popping 70% during their first day of trading on the Nasdaq. At press time, Compass Pathways’ market cap had ballooned to over $1.42 billion, making it the most valuable psychedelics company in the world.

Even celebrity businessmen like former Canopy Growth CEO Bruce Linton and Dragon’s Den and Shark Tank star Kevin O’Leary have gotten into psychedelics the game.

But where real value and opportunity often reside is in the domain of small capitalization companies. Now, savvy investors are looking at a number of aggressively positioned small caps that are moving rapidly to grab attention and gain traction within capital markets.

One such company is Numinus Wellness Inc. (NUMI) (TSX-V.NUMI, OTCMKTS: LKYSF, Forum) a relatively new player in the space that is advancing psychedelic laboratory testing, therapy, and research, and hope to create a lifelong relationship between the Company and its clientsa journey to heal and be well.”

NUMI’s unique ecosystem of health solutions is centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies to treat a myriad of mental health ailments, primarily depression and drug & alcohol addiction. The Company recently announced announce it has commenced cultivating psilocybin mushrooms at its 7000 square-foot Health Canada-licensed facility.

In a recent Stockhouse article, our investor audience was introduced to a soon-to-be-CSE-listed Company that’s advancing psychedelic and nutraceutical-based products. Cybin Corp. (P.CYBN, Forum) is launching psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.

Vancouver BC-based Universal Ibogaine Inc. (UI) (P.IBO, Forum) has a slightly different business model, currently focussed on addressing the opioid epidemic through proven plant medicine ibogaine. The Company operates franchise clinics with a safe and effective, seven-day treatment with ibogaine to deal with the opioid crisis, changing attitudes towards vibrant new medical solutions.

The detox treatment has been developed and tested by Cancun MX-based Clear Sky Recovery and has proven to be a superior alternative to standard treatments, pharmaceuticals, natural medicines, and recovery centreswith success rates estimated between 45 to 60%. With standard treatment centres achieving a typical recovery rate of about 4%, the ibogaine / Clear Sky Recovery method has demonstrated a ten-fold improvement over traditional treatment programs.

With its corporate motto, from Underground to Mainstream” Red Light Holland Corp. (TRIP) (CSE: TRIP, OTC: ACPQF, Forum) has carved out its niche in the magic truffle’ business. With a distinctly different business model from aforementioned treatment-based psychedelics companies, TRIP is now positioned to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands.”

In addition, Red Light Holland recently reached several distribution arrangements for their iMicrodose packs which will be sold in several locations around the Netherlands for adult usage. Todd Shapiro, CEO and Director of Red Light Holland is very proud to be able to say that they are selling the first legal psilocybin product in the world and he looks forward to reaching new markets in the future, which he doesn’t think is too far off.

The Company is currently growing three different strains of magic truffles and expects to have an initial batch of approximately 100,000 grams of magic truffles available in late October 2020.

Stockhouse investors are gaining increasing insight into the scientific and medical marvels that psychedelic treatment can effectively provide people suffering from a wide variety of debilitating mental health issues, along with drug dependency and abuse.

Stay tuned to Stockhouse in the upcoming months for continuing news updates and investors alerts surrounding the burgeoning psilocybin / psychedelics marketplace.

FULL DISCLOSURE: Red Light Holland Corp., Numinus Wellness Inc., Cybin Corp. and Universal Ibogaine Inc. are clients of Stockhouse Publishing.

Here is the original post:

Opening the Door to the New Psychedelics Revolution | 2020-10-09 | Investing News - Stockhouse